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SUMMARY
This study was undertaken to assess the Matrix 96 Direct Beta Counter for the 
measurement of Chromium (^^Cr)-release from cytotoxic T lymphocyte precursor 
(CTLp) frequency assays of human cardiac transplant recipients. The Matrix 96 was 
compared with a gamma counter for the measurement of maximal ^^Cr-release from 
graded numbers of labelled target cells. Repeated counts by both counters were 
consistent. Variation between the Matrix 96 and the gamma counter was similar to the 
variation between repeated counts using the gamma counter, indicating that the counters 
were comparable for the measurement of ^ ^Cr. The contribution of natural killer-like 
activity to target cell killing in the CTLp assay was investigated by the use of the K562 
cell line in cold target competition assays. Ten responder-stimulator combinations were 
tested in the CTLp assay for cross-reactivity between K562 and allogeneic targets. 
Cytotoxicity was reduced in only one assay, suggesting that the cells which mediated 
lysis of allogeneic lymphocytes and K562 cells recognised distinct targets. Donor- and 
3'^ '^  party-reactive CTLp frequencies in 15 human cardiac allograft recipients were then 
measured in samples taken before transplantation, and at two intervals after 
transplantation. In the group of patients, donor-reactive CTLp frequencies decreased by 
3 to 7 months after transplantation, but increased to pre-transplant levels by 9 to 15 
months after transplantation. Donor-specific decreases in CTLp frequencies relative to 
the pre-transplant frequencies were found in three patients by 9 to 15 months after 
transplantation. Pre-transplant donor-reactive CTLp frequencies were not predictive of 
acute rejection in the first 3 months or in the first year after transplantation. Donor- 
reactive CTLp frequencies were lower at 9 to 15 months after transplantation in patients
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with concurrent endomyocardial biopsy (EMB) grade 2 or 3 rejection than in patients 
without rejection (EMB grade 0 or 1). Similarly, a negative correlation was found 
between donor-reactive CTLp frequencies at 9 to 15 months after transplantation and the 
number of EMB graded >2 in this period. Donor-reactive CTLp frequencies were not 
significantly different in patients who received induction immunosuppression with anti­
thymocyte globulin (ATG) and in patients who received standard triple 
immunosuppression. The conclusion of all these experiments was that the Matrix 96 was 
comparable to the gamma counter for the measurement of ^ ^Cr-release and was a rapid 
and convenient method for counting large numbers of limiting dilution assays.
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INTRODUCTION
1. The measurement of ^  Chromium-release in cell-culture 
supernatants using the Matrix 96 Direct Beta Counter.
Cytotoxic lymphocytes are cells of the immune system which can kill certain pathogen- 
infected cells, tumour cells and transplanted tissues (1). The cytotoxic activity of such 
cells is measured in vitro using cytolytic assays. Cytotoxic lymphocytes are cultured 
with target cells which have been labelled internally with a radioisotope or non­
radioactive label After four hours or longer incubation the amount of label released to 
the supernatant from lysed target cells is measured, giving an indication of the cytotoxic 
activity (2, 3).
The standard method of measuring cell-mediated cytotoxicity is by labelling target cells 
with the radioisotope ^^Cr in the form of sodium chromate (Na2 ^^Cr0 4 ). The 
radioactivity released from lysed cells is usually counted using a gamma counter (2). 
Gamma rays released from a sample cause the release of scintillations of light from a 
crystal and a detector system sorts and counts the emissions according to their 
energies (4). ^^Cr is counted in the 240 - 400 nm wavelength band and the result is 
expressed as counts per minute (cpm). Depending on the design of the gamma counter, 
samples may be counted sequentially, with the disadvantage that when the assay is large 
it can take several hours to count all samples. Alternative methods have been described, 
including the detection of the non-radioactive label europium (3, 5) or the enzyme lactate 
dehydrogenase (6) after target cell lysis. Non-radio active methods are not widely used,
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however, and the measurement of ^ ^Cr-release remains the most common detection 
method in assays of cell-mediated cytotoxicity.
^^Cr decays by electron capture, emitting beta particles as well as gamma radiation (7). 
Beta particles emitted by ^^Cr have been measured by scintillation counting, in which the 
sample is added to a liquid or solid scintillant and is counted in a beta counter (8 - 10). 
The Matrix 96 Direct Beta Counter can be used to count beta particles released from 
^^Cr directly, without the need for scintillants. The Matrix 96 is a computer controlled 
beta counter which can simultaneously count 96 samples in the format of a 96 well 
microplate. It uses ninety-six uniform and independent avalanche gas ionisation 
detectors operating in the Geiger-Muller and proportional counting modes to maximise 
counting efficiency for weak beta and gamma isotopes (11). Samples to be counted are 
transferred and dried onto a “spotting” plate, which consists of a flat metal plate on 
which the pattern of a 96 well plate has been printed with hydrophobic ink. Sample 
preparation is thus more readily achieved than with a standard gamma counter, for which 
samples need to be transferred to individual tubes, which are then sealed. As samples 
from all the wells of a culture plate are counted simultaneously, the entire assay can be 
counted in a shorter time than if samples were counted sequentially.
The Matrix 96 correlated well with a gamma counter for the measurement of ^ ^Cr-release 
from cell-mediated lympholysis assays of lymphokine activated killer cells with tumour 
cell line targets (12). Similar percentage cytotoxicity was also found when a gamma 
counter was compared to the Matrix 96 in a ^^Cr retention assay, in which unlysed cells 
were harvested onto a fibre filter before counting (13). However, the assessment of the 
Matrix 96 for the measurement of ^^Cr-release in the above study involved the use of
18
correlation co-efficients (12). Correlation co-efficients measure strength of linear 
association, which is not the same as agreement, so this is not the most appropriate 
approach to method comparison studies (14). Methods of assessing agreement which 
give a useful indication of the differences between two methods are more 
informative (14).
Frequencies of cytotoxic T lymphocyte precursors (CTLp) in mixed cell populations can 
be estimated by limiting dilution assays (15). In each CTLp assay cytotoxicity is typically 
measured in at least 192 culture wells (16, 17) and studies often involve the testing of 
many samples (18, 19), so many culture supernatants need to be counted for ^^Cr. The 
96-detector design of the Matrix 96 is ideally suited for this purpose.
The use of the Matrix 96 for measuring ^^Cr-release in CTLp assays has not been 
reported. To determine its suitability for such assays, the Matrix 96 was compared with 
a gamma counter by measuring ^^Cr-release from graded numbers of detergent-lysed 
phytohaemagglutinin (PHA)-stimulated lymphoid blast cells which gave a range of values 
that could be expected in CTLp assays. The method of analysis assessed the agreement 
and repeatability of the counting methods to give a useful indication of the differences 
between the two methods. ^^Cr-release from CTLp assays of cardiac transplant 
recipients was then measured to assess the suitability of the Matrix 96 for counting large 
numbers of limiting dilution assays in a clinical setting.
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2. CTLp frequency analysis in human cardiac transplant recipients.
2.1. Cytotoxic lymphocytes and cardiac transplantation.
2.1.1. Histocompatibility genes and molecules.
Experiments in tumour and skin grafting between inbred mouse strains led to the 
identification of a single genetic region mainly responsible for the rejection of tissues 
from a genetically different, or allogeneic, individual of the same species (20, 21). Tliis 
region was named the major histocompatibility complex (MHC), and in the mouse was 
called H-2 (22). The human equivalent is the human leukocyte antigen (HLA) complex, 
which is located on the short arm of chromosome six (23). An antigen is defined as a 
molecule which can be specifically bound by an antibody molecule (24).
MHC genes are classified in two groups, class I and class II, based on stmctural 
similarities between the members of each group (25). MHC class I and class II genes 
encode cell-surface glycoproteins which are involved in immune recognition (26, 27). 
HLA-A, -B and -C class I genes, and certain loci of the HLA-DR, -DQ and -DP class II 
genes encode functional HLA molecules which are expressed on cell surfaces (28). The 
expression of HLA genes is codominant, that is, an individual expresses two HLA alleles 
at each locus, one inherited from each parent (29). HLA genes are highly polymorphic, 
numbering several hundred class I and II alleles (28).
Class I HLA molecules consist of a polymorphic, HLA-encoded a  polypeptide chain of 
about 44kD which is non-covalently associated with beta2 -microglobulin, an invariant
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12 kD polypeptide encoded on chromosome 15 (30, 31). Class II HLA molecules 
consist of two non-covalently associated, polymorphic, HLA-encoded polypeptide 
chains: an a  chain of about 34 kD and a |3 chain of about 29 kD (32, 33). Both class I 
and class II HLA molecules contain immunoglobulin-like loops or domains formed by 
disulphide bonds (34, 35).
The three-dimensional structures of HLA molecules were determined using X-ray 
crystallography, which confirmed similar structures for class I and class II molecules. 
Notable was a cleft or groove formed by polypeptide in the form of p-pleated sheet and 
a-helices, in which was found a short peptide (36, 37). Most of the polymorphism in 
HLA molecules occurs in the peptide-binding regions which are formed by the a l  and 
a2  domains of class I molecules and the a l  and p i domains of class II molecules (38, 
39). The peptides bound by MHC molecules are usually derived from normal cellular 
proteins, but during infections the bound peptides may be derived from pathogens (40). 
Such foreign peptides bound by MHC molecules are recognised by T lymphocytes during 
an immune response to the pathogen (41, 42).
Class I HLA molecules are constitutionally expressed on many cells and tissues, but the 
expression of class II HLA molecules is normally restricted to a limited number of cell 
types, including macrophages, dendritic cells, monocytes, B cells, activated T cells and 
also human endothelial and epithelial cells (43). HLA class I and II molecule expression 
can be upregulated by cytokines, soluble mediators produced by cells of the immune 
system (44, 45).
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Matching of HLA antigens between recipients and donors is beneficial in cadaveric renal 
transplantation (46, 47). The selection of HLA matched recipients for cardiac 
transplantation has been limited by the short preservation time of donor hearts, but 
retrospective studies have demonstrated an effect of HLA matching on graft survival and 
cellular rejection (48 - 50).
Certain genes outwith the MHC encode antigens which give rise to weak or slow 
rejection responses. Such antigens have been termed minor histocompatibility antigens, 
but these can nevertheless stimulate rejection of transplanted organs (51). Minor 
histocompatibility antigens are peptides derived from polymorphic cellular proteins which 
are naturally processed and presented by MHC molecules (52).
2.1.2. Lymphocytes.
Lymphocytes are cells of the immune system, present in the blood and lymphoid tissues, 
which can specifically recognise foreign antigens (53). Lymphocytes and mononuclear 
phagocytes form the mononuclear cell component of white blood cells, or leukocytes. 
The three major classes of lymphocytes are T cells, B cells and natural killer cells.
T cells express T cell receptors (TCR) which recognise foreign peptides presented in 
association with self MHC molecules on cell surfaces (54, 55). The receptor specific for 
antigenic peptide-MHC complexes which is expressed by the majority of T lymphocytes 
is a heterodimer consisting of a  and (3 polypeptide chains. The ap  TCR is associated 
with CD3 proteins and other invariant proteins to form the T cell receptor complex (56).
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A minority of T cells express the yô receptor, the flinction of which is not fully 
understood (57).
Each T cell clone expresses T cell receptors of a unique specificity (54). The repertoire 
of specificities of a|3 T cells is formed during T cell development in the thymus. A large 
repertoire of immature T cells is generated by somatic rearrangement of TCR gene 
segments which can then be combined in different ways, with further diversity arising 
when the rearranged segments are joined (58). The mature T cell repertoire is then 
shaped by a process involving positive selection of self MHC-restricted T cells and clonal 
deletion of autoreactive T cells (59).
In addition to the antigen receptors and MHC molecules already referred to, membrane 
proteins expressed by lymphocyte populations can be identified by specific monoclonal 
antibodies which define “clusters of differentiation” or CD markers (60). 
ap  T lymphocytes can be categorised as being of two major groups, depending on 
mutually exclusive expression on the cell surface of either CD4 or CDS molecules.
CD4 +ve T cells recognise antigen presented by class II MHC molecules and CDS +ve 
T cells recognise antigen presented by class I MHC molecules (61, 62). Classically,
CD4 +ve T cells are regarded as cytokine-secreting “helper” T cells, whereas CDS +ve 
T cells are seen as cytotoxic cells (63). These distinctions are not absolute, however, as 
CD4 +ve T cells can also be cytotoxic (64, 65), and CDS +ve T cells secrete certain 
cytokines, notably interferon-y (IFN-y) (66, 67). T cells can also suppress immune 
responses in certain circumstances, but this activity may be mediated by particular
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functions of subsets of both CD4 +ve and CDS +ve T cells rather than by a distinct 
lineage of suppressor T cells (68).
In contrast to the TCR, the B lymphocyte antigen receptor recognises soluble or cell- 
surface antigens without the requirement for processing and presentation by MHC 
molecules. The proliferation and differentiation of B lymphocytes in response to most 
protein antigens is, however, dependent on help from T lymphocytes (69). B lymphocyte 
antigen receptors consist of membrane-bound forms of immunoglobulin molecules (70). 
Plasma cells, the terminally differentiated form of B lymphocytes, secrete 
immunoglobulin molecules of identical specificity to the membrane-bound form that was 
the initial trigger by wliich the B lymphocyte was activated (71). Secreted 
immunoglobulin molecules, also known as antibodies, have a variety of effector 
functions, including neutralisation of antigen, activation of serum proteins of the 
complement system, and coating of pathogens for enhanced removal by 
macrophages (72).
Natural killer (NK) cells, the third major class of lymphocytes, are large granular 
lymphocytes which do not express the T cell receptor, CD3 or membrane-bound 
immunoglobulin but commonly express CD 16 (the low affinity receptor for IgG) and 
CD56 molecules (73). NK cells can kill certain tumour cells and other normal cells and 
cultured cell lines without prior sensitisation and in a non-MHC restricted manner (74). 
NK cells can thus kill targets which do not express MHC molecules, such as the human 
haematopoietic tumour cell line K562 (75). The function of NK cells is not fully 
understood, but they may provide a defence against virus-infected or tumour cells with 
reduced or absent MHC class I expression (76).
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2.1.3. T lymphocyte activation and differentiation.
Resting T cells which have not encountered antigen are known as naïve or precursor 
T cells, and need to be activated by foreign antigen to develop effector functions (77). 
Activation occurs following the presentation of antigenic peptide-MHC complexes to 
T cells on the surfaces of antigen-presenting cells (APC). Two kinds of signal are 
required from APC to activate naive T cells (78). One is the result of the engagement of 
the TCR and its CD4 or CDS co-receptor with an immunogenic peptide-MHC complex. 
The second signal is provided by non-polymorphic molecules on the surface of the APC 
which deliver essential costimulation to T cells. The best characterised costimulators are 
CD80 and CD86, members of the B7 ligand family, which interact with CD28 on T cells 
(79). Interactions of other adhesion molecules such as lymphocyte function-associated 
antigen (LFA)-1 with intercellular adhesion molecule (ICAM)-1 and ICAM-3, and CD2 
with LFA-3 also enhance activation, but appear to be of lesser importance than the 
CD28 - B7 interactions (77). Naïve CD4 +ve T cells can only be activated by APC 
which provide the necessary costimulatory signals, but once activated T cells seem not to 
require costimulation and are able to respond to some extent to any APC bearing the 
appropriate peptide-MHC complex (77, 80). T cells which have been activated in vivo 
are sometimes described as “committed”. Mature dendritic cells express liigh levels of 
MHC molecules as well as adhesion and costimulatory molecules, and are particularly 
potent activators of naive T cells (81).
T cell receptor binding to the antigenic peptide-MHC complex together with 
costimulatory signals activates intracellular signal transduction pathways (82). 
Intracellular portions of the CD3-y, -5, -s and chains contain immunoreceptor
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tyrosine-based activation motifs which are phosphorylated by the protein tyrosine kinases 
Fyn and Lck of the Src family. Ligation of CD4 or CDS co-receptors by their MHC 
molecule ligands activates associated Lck protein tyrosine kinases. The phosphorylated 
TCR receptor complex ^ chain binds and activates zeta-associated protein (ZAP)-70, a 
Syk-family member protein tyrosine kinase which is required for T cell activation (83). 
These processes lead to the formation of at least two second messengers, inositol 
triphosphate and diacylglycerol, which bring about an increase in the concentration of 
intracellular Ca^  ^and activate protein kinase C (82). Ca^  ^ ions bind to the protein 
calmodulin, forming a calmodulin-Ca^^ complex which activates calcineurin, a protein 
phosphatase. Calcineurin dephosphorylates the cytoplasmic subunit of the nuclear factor 
of activated T cells (NF-AT), which moves to the nucleus and combines with nuclear 
MF-AT to form a functional transcription factor (84). Functional NF-AT promotes the 
expression of interleukin-2 (IL-2) (84), a key regulatory cytokine in T cell activation. 
Protein kinase C plays a role in pathways leading to the activation of transcription factors 
(85). TCR stimulation also activates the Ras protein, which initiates a pathway leading 
to the induction of a calcium-independent nuclear component of NF-AT (86). Other 
transcription factors expressed rapidly after T cell activation include NF-kB, c - F o s  and 
c-Myc. These early-immediate events are followed within hours of stimulation by the 
expression of genes encoding several cytokines, including IL-2 and IFN-y, the alpha 
chain of the IL-2 receptor, and various other receptors and adhesion molecules (87),
The expression of IL-2 and the high-affinity IL-2 receptor is required for T cell 
proliferation. The IL-2 receptor (IL-2R) consists of three subunits, the a , (3 and y 
polypeptide chains (88). The high affinity form of the receptor consists of the a  and j3
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subunits (89), together with the more recently characterised y chain. The y chain does 
not bind IL-2 directly but appears to be involved in signalling and forms the intermediate- 
affinity IL-2R together with the P chain (90). The IL-2R p and y chains are associated 
with protein tyrosine kinases of the Jak, Src and Syk families which, when activated, 
initiate multiple signal transduction pathways (91). Signalling mediated by the binding of 
IL-2 to the high affinity IL-2 R promotes the transition of the T cell from the Gi to the 
S phase of the cell cycle and so to cell division (92).
Differentiation to effector cells occurs several days after stimulation and is accompanied 
by the expression of late activation antigens such as MHC class II molecules (93) and 
members of the p i integrin family (94). During this period cytotoxic T lymphocytes 
synthesise the lytic proteins which are later used in target cell killing (95).
The development of cytotoxicity by CD8 +ve T cells is usually dependent on help from 
CD4 +ve T cells (96, 97). This may be in the form of cytokines, of which IL-2 and 
IFN-y are considered to have significant roles (98, 99). Other cytokines, including IL-4, 
IL-6, IL-7 and IL-12 have also been reported to provide help for the generation of CTL 
(100 - 103). It has also been suggested that the role of the helper T cell may be to 
deliver an activating signal to the APC, permitting the APC to stimulate the CD8+ve 
T cell directly (104). The interaction between CD40 ligand on helper T cells and CD40 
on the APC is thought to provide such a signal (105 - 107). Certain subsets of CDS +ve 
T cells can also be activated directly by dendritic cells in the absence of CD4 +ve 
T cells (108, 109). Costimulation by CD80 and CD86 can provide the second signal in 
this model (110). Such helper T cell-independent activation of CDS +ve T cells may
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result from the ability of the CD8 +ve T cell to produce and respond to IL-2 in an 
autocrine manner (111). The contribution of CD4 +ve-T cell-independent CD8 +ve 
T cells to in vivo alloreactivity in humans is not known, but HLA class II differences are 
usually considered necessaiy for reactivity in mixed lymphocyte culture (MLC) 
in vitro {111, 113).
After encountering antigen some T cells differentiate into memory cells. These are 
resting cells wliich develop effector functions on re-stimulation with specific antigen, 
producing a faster, stronger response than occurs with primaiy stimulation of naïve 
T cells (114). Memory T cells can be differentiated from naïve T cells by positivity or 
negativity for the different isoforms of the CD45 molecule. In humans memory T cells 
are chiefly characterised as CD45RO positive and CD45RA negative, whereas naïve 
T cells are CD45RA positive and CD45RO negative (115). Effector cells share some 
surface markers with memory cells, however, so effector and memory cells cannot be 
clearly distinguished from each other by phenotype alone (116). Memory T cells are 
present at higher frequencies than naïve T cells and have higher affinity for antigen (117). 
Memory T cells are also more readily activated than naïve T cells and require less co­
stimulation; resting B cells and macrophages can activate memory T cells whereas naïve 
T cells require dendritic cells or activated B cells for activation (118, 119).
When resting T cells are stimulated through the TCR in the absence of co stimulatory 
signals they become unresponsive to subsequent stimulation by APC which do express 
the required co stimulator molecules. Tliis state has been described as T cell clonal 
anergy, and is characterised by an inability of the T cell to produce IL-2 (120). T cell
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anergy may contribute to peripheral tolerance towards self or allogeneic antigens (121). 
The anergic state can be reversed by stimulation with high concentrations of IL-2 (122).
2.1.4. T lymphocyte-mediated cytotoxicity.
T lymphocyte-mediated cytotoxicity is antigen-specific. Effector CTL recognise peptide- 
MHC complexes on target cells by their TCR complexes. The formation of a CTL- 
target cell conjugate is initiated by weak interactions between adhesion molecules such as 
CD2 and LFA-1 and their respective ligands LFA-3 and ICAM-1. TCR binding 
activates CD8, LFA-1 and veiy late activation integrins which bind their receptors, 
strengthening the conjugate and providing additional costimulatory signals (95, 123). 
Specifically recognised target cells are then killed by the CTL.
There are two main mechanisms by which lymphocytes kill target cells. The first is 
mediated by perforin and granzymes, soluble proteins which are released from 
cytoplasmic lytic granules in the CTL. TCR-mediated recognition and conjugate 
formation triggers the movement of the lytic granules towards the point of contact with 
the target cell, followed by exocytosis of the granules' contents (124). Perforin 
polymerises and forms pores in the target cell membrane which can lead to osmotic lysis 
and necrotic cell death (125). In the presence of perforin, granzyme proteases enter the 
target cell and activate proteolytic caspases (cysteine aspartases) which cleave cellular 
proteins leading to death by apoptosis (126). Apoptic cell death is characterised by 
chromatin condensation, DNA fragmentation and blebbing of the cell membrane (127).
29
The second main killing mechanism is mediated by the interaction between Fas-ligand 
(FasL) on the membrane of the CTL and the Fas receptor (CD95) on the target cell 
surface. Cross-linking of Fas by FasL initiates a cascade of protein interactions leading to 
the activation of intracellular caspases and the induction of apoptic cell death (128). 
Other related molecules, such as tumour necrosis factor (TNF) and TNF-related 
apoptosis-inducing ligand can induce apoptosis in a similar way to Fas after binding to a 
corresponding “death receptor” (129).
The effector CTL is not itself lysed in the killing process. After lysis, the CTL 
disengages the target cell and is able to kill additional targets (95). Effector CTL 
flinction is short-lived, however, and most effector CTL die within one to five days or 
become memory cells (130).
2.1.5. Natural killer cell-mediated cytotoxicity.
In contrast to T cells, which kill target cells recognised through the TCR, NK cells 
express inhibitoiy receptors which recognise polymorphic class I MHC molecules and 
prevent the lysis of recognised cells (131). In this way, NK cells are prevented from 
killing the individual’s own normal cells. In humans, the inhibitoiy receptors are the 
CD94/NKG2 receptors, which belong to the C-type lectin superfamily, and the killer cell 
inhibitory receptors (KIR), which are members of the immunoglobulin superfamily (132). 
CD94/NKG2 receptors bind to HLA-E, a non-classical HLA class I molecule (133), 
whereas KIR recognise HLA-B and -C molecules (132). These receptors possess
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immunoreceptor tyrosine-based inhibitory motif (ITIM) sequences in their cytoplasmic 
domains wliich mediate the inhibitory signals (134, 135).
The interactions through which NK cells are stimulated to kill target cells are not well 
understood. The ligation of membrane receptors such as CD2, CD69 and CD44 may 
provide activation signals (136 - 138). Other proteins which may function as activating 
receptors include NKR-Pl (139), certain members of the CD94/NKG2 family of 
receptor complexes (140, 141) and KIR with short cytoplasmic domains that lack the 
ITIM motif (142, 143). Receptors associated with such ITIM-lacking KIR may mediate 
activation of the NK cell (144, 145). The ability to lyse targets is thought to depend on 
the balance between the activating and inhibitoiy signals received by the NK cell (131, 
146).
The mechanisms used by NK cells to kill target cells are the same as those used by CTL, 
namely granule exocytosis and Fas-L-mediated apoptosis (95, 147). NK cells can also be 
activated by ligation of their CD 16 receptors by IgG antibodies coating a target cell.
NK cells activated in this way mediate antibody-dependent, cell-mediated cytotoxicity 
(148, 149).
Peripheral blood or spleen lymphocytes stimulated with high concentrations of IL-2 
acquire the ability to lyse a variety of target cells, including NK-sensitive and 
NK-resistant tumour cells, in a non-MHC restricted fashion (150, 151). Such cells have 
been called lymphokine-activated killer (LAK) cells and are NK-like cells or non-MHC 
restricted T cells (152).
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The activity of NK cells can be regulated by cytokines. IL-2 enhances the cytotoxic 
activity of NK cells, and induces them to proliferate and produce several cytokines, 
including IFN-y (153 - 155). The IL-2R P chain is expressed on most NK cells and 
mediates signal transduction when bound by IL-2 (156). The IL-2R a  chain can be 
induced on most NK cells by IL-2 (157) and forms the high affinity IL-2R in conjunction 
with the p and y chains. Enhanced cytotoxicity and LAK activity, and the induction of 
proliferation are mediated by the intermediate-affinity IL-2R, but the a  chain and high- 
affinity IL-2R binding is required for maintenance of proliferation and cytokine 
secretion (158).
IL-6 enhances NK cell cytotoxic activity in mononuclear cell cultures by inducing IL-2 
production (159). LAK activity is induced in peripheral blood mononuclear cell cultures 
by IL-7 (102, 160). IL-12 enhances NK activity in peripheral blood lymphocytes and 
stimulates IFN-y production (161, 162), but has little effect on proliferation (163).
The interferons (IFN-a, -p, and -y) can have varying effects on NK cell cytotoxicity. 
IFN-a and -y can enhance NK cell cytotoxic activity alone or in combination with IL-2, 
but prolonged co-culture of IFN-y and IL-2 for more than six days inhibits cytotoxicity 
(164, 165). TNF induces IL-2Ra expression, proliferation and LAK activity in NK cells 
in combination with IL-2 (166, 167). IL-4 inhibits the enhancement of NK cell cytotoxic 
activity and proliferation by IL-2 (168), but induces proliferation of NK cells in 
combination with IL-12 (169).
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Cytokines mediate their effects by binding to specific cytokine receptors. Most cytokine 
receptors lack intrinsic protein tyrosine kinase domains, but induce intracellular signal 
transduction by the recmitment or activation of cytoplasmic protein tyrosine 
kinases (91).
CTL cultured in the presence of IL-2 can also develop non-MHC restricted cytotoxicity 
(170). Cells cultured in IL-2 that have NK activity have therefore been called cells with 
NK-like activity to distinguish them from freshly-isolated NK cells (171). This 
terminology has been adopted here to describe cells mediating the lysis of the NK cell 
target K562 after in vitro culture.
2.1.6. Allorecognition.
T cells recognise allogeneic MHC molecules in two main ways, termed direct and 
indirect allorecognition. In direct allorecognition, T cells recognise intact antigenic 
peptide-MHC complexes on the surface of allogeneic antigen presenting cells. The 
antigen-specific and allo-specific T cell repertoires overlap, suggesting that direct 
allorecognition is a result of cross-reactivity of self-restricted T cells (172, 173). About 
1 - 10 % of T cells can respond to an alio antigen, a much higher frequency than is found 
for conventional antigens (174). This high frequency of allorecognition could be 
explained by two models of the interaction between T cells and allogeneic MHC: the 
multiple determinant model and the high ligand density model (175). In the multiple 
determinant model, the peptide bound by an allogeneic MHC molecule forms part of the 
antigenic determinant recognised by the T cell receptor. Different MHC molecules bind
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peptides with distinct sequence motifs (176, 177), and each MHC molecule can bind in 
the region of 2000 to 10000 different peptides (178). Allogeneic MHC molecules 
therefore present a different set of bound peptides from self-MHC molecules. Thus a 
single allogeneic MHC molecule could give rise to many different antigenic peptide- 
MHC complexes and stimulate many different T cells. In the high ligand density model 
the T cell receptor interacts with antigenic determinants on the allogeneic MHC molecule 
itself, irrespective of the bound peptide. This could result from TCR specific for 
antigenic peptides presented by self-MHC cross-reacting with determinants on the TCR- 
contacting parts of an allogeneic MHC molecule (179). MHC molecules are present on 
APC at high density and so could be recognised by large numbers of T cells, including 
those with low-affinity receptors which would not normally be stimulated by lower 
density ligands (180). Peptide-specific and MHC-specific allorecognition could operate 
in different circumstances, depending on the stmctural similarity of the responder and 
stimulator MHC molecules. When responder and stimulator MHC molecules are similar, 
the bound peptide may be the major recognition element, but when the MHC molecules 
are very different, determinants on the allogeneic MHC molecule itself may contribute 
more (179).
In the second allorecognition pathway, T cells recognise alio antigen-derived peptides 
presented by host APC in the context of self-MHC in a process known as “indirect” 
presentation (181). This is analogous to conventional self-MHC restricted antigen 
recognition.
CD8 +ve cytotoxic T lymphocytes recognise allogeneic target cells directly, but indirect 
presentation of alloantigens may contribute to CD4 +ve T cell helper or regulator
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responses (182, 183). Helper T lymphocytes activated by the indirect presentation 
pathway can induce delayed-type hypersensitivity (DTH)-type responses, CD8 +ve 
T cell-mediated cytotoxicity and antibody production by B cells in animal models (184).
2.1.7. Cardiac allograft rejection.
Allograft rejection can take different forms which are defined on the basis of the time 
after transplantation at which they occur and the histopathology of biopsy specimens or 
of the rejected organ (185).
Hyperacute rejection occurs within hours of transplantation and is mediated by pre­
existing antibodies that bind to graft vascular endothelium (186, 187). The binding of 
antibody activates complement and effects changes in vascular endothelial cells, leading 
to increased vascular permeability, the attraction of phagocytes, platelet aggregation and 
the attraction of inflammatoiy cells such as neutrophils and platelets (188). In cardiac 
allografts hyperacute rejection is characterised histologically by dismption of the 
microcirculation with interstitial haemorrhage and oedema (189, 190) and results in heart 
failure. Hyperacute rejection of transplanted hearts is rare (191 - 193), but has been 
reported after the transplantation of blood group ABO incompatible hearts (194), in 
some but not all patients with a positive lymphocytotoxic crossmatch (190, 193, 195, 
196), and in some patients with a negative lympho cytotoxic crossmatch but with 
antibody to vascular endothelial cells or other myocardial proteins (187, 197, 198).
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Acute cardiac allograft rejection occurs most frequently in the first few months after 
transplantation, and is inft equent after the first year (199, 200). Acute cellular rejection 
is monitored by endomyocardial biopsy (EMB) (201) and is characterised by infiltration 
of the heart by inflammatoiy leukocytes, accompanied by myocyte damage in the 
moderate and severe forms. The cellular infiltrate can comprise lymphocytes, including 
CD4 +ve and CDS +ve T lymphocytes, B lymphocytes and NK cells; monocytes and 
macrophages; and granulocytes (202 ~ 204).
CD3 +ve T cells increase in number in biopsies showing histological rejection, but the 
relative proportions of CD4 +ve and CDS +ve T cells observed is influenced by the type 
of immunosuppression received by the patients (205). Before the introduction of 
cyclosporin A (CsA), CDS +ve T cells predominated during rejection, but a mixed 
infiltrate of CD4 +ve and CDS +ve T cells is seen in CsA-treated patients (202, 206, 
207). The activation status of graft infiltrating cells has also been studied. An 
immunohistological analysis of CD45 isoforms in EMB showed that during mild 
rejection naïve CD45RA, CD4 +ve T cells predominated, whereas during moderate 
rejection there was a shift towards activated CD45RO T cells, with the greatest increase 
in CD45RO, CDS +ve cells (208). Activated CTL express perforin and granzymes and 
both mRNA encoding these proteins, and the proteins themselves have been found in 
association with histological rejection (209, 210).
Increased expression of HLA class I and class II molecules is found in EMB, often but 
not always corresponding with histological rejection (205). HLA class I is upregulated 
on the myocardial plasma membrane and intercalating discs, and HLA class II is 
upregulated on vascular endothelium and on the endocardium (205). Increased HLA
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expression is presumably induced by cytokines released from infiltrating cells. The 
expression of adhesion molecules ICAM-1 and vascular cell adhesion molecule 
(VCAM)-l are also upregulated in EMB during rejection and are involved in migration 
of lymphocytes through the endothelium and into the graft (211).
Anti-heart and donor cell-reactive antibodies have been found in association with cellular 
rejection and may contribute to acute rejection (198, 212, 213). Antibody-mediated 
acute (“vascular”) rejection has also been described in the absence of cell-mediated 
rejection (214).
Chronic rejection of cardiac allografts takes the form of accelerated coronaiy aiteiy 
disease (CAD) (215). CAD is visible by angiography in 10 - 15 % of patients after one 
year and 40 - 50 % of patients after five years (216, 217) but as many as 75 % of patients 
show intimai thickening at 1 year by intravascular ultrasonography (218). Both humoral 
(219, 220) and cell-mediated (221, 222) mechanisms may be involved in the 
pathogenesis of CAD, although non-immunological factors also contribute (215).
Rejection in recipients previously unsensitised to donor alloantigens is initiated by host 
T cells which have been activated by alloantigens of the graft (223). The cells thought to 
be primarily responsible for the initiation of rejection by the direct allorecognition 
pathway are MHC class Il-positive “passenger” leukocytes of donor origin which are 
present within the transplanted graft (224, 225). Dendritic-like cells have been found in 
normal rat and mouse hearts (226, 227), and in normal human hearts, although in the 
latter they form a minority of class Il-positive cells (228). In mice, dendritic leukocytes 
have been shown to migrate from transplanted hearts to the spleen, where central
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activation of T cells could occur (227). It is also possible that T cells could be activated 
by donor passenger leukocytes within the graft itself (229).
Graft endothelial cells may be able to directly activate alloreactive memory, but not naive 
T cells (230), and although the response is relatively weak it may increase the number of 
activated T cells in the graft (231). Approximately 20 % of the primary CTL precursor 
response to class I alloantigen can be activated by antigen alone, without costimulation, 
and so may represent cross-reactive memory CTL primed by environmental 
antigens (119).
Activated helper T cells of the host release cytokines which to act the recipient’s 
lymphoid cells and on graft tissue to promote the effector mechanisms that result in 
rejection (232 - 234). T cell-derived cytokines provide help for the activation of CTL 
and antibody production, and bring about DTH-type responses through inflammation and 
macrophage activation (185). CD4 +ve T cells may also be directly cytotoxic to the 
graft (235).
If prior sensitisation to donor alloantigens has occurred, donor antigen-reactive memory 
T cells may also be present, and as discussed above, memoiy T cells are more readily 
activated than naïve T cells. Memory CD8 +ve T cells are also less dependent on CD4 
+ve T cells for help and both memory CD4 +ve and CD8 +ve T cells are more potent 
mediators of rejection than naïve T cells (233, 236, 237).
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2.1.8. The role of cytotoxic T lymphocytes in cardiac allograft rejection.
Whether allograft rejection is mediated by specific CTL or by CD4 +ve T cell-mediated 
DTH-type mechanisms has been the subject of debate between workers studying animal 
models of transplantation and rejection (238, 239). The rejection of organ allografts can 
be delayed or abrogated in animals depleted of CD4 +ve T cells but not in animals 
depleted of CD8 +ve T cells (240 - 243). However, there is evidence from adoptive 
transfer studies of collaboration between CD4 +ve and CD8 +ve T cell subsets in 
rejection (244 - 246), and for antigen-specific as well as non-specific tissue damage 
(247 - 249). It is now generally accepted that both CD4 +ve and CD8 +ve T cells 
contribute to allograft rejection by a combination of CTL-mediated and DTH-type 
mechanisms (250, 251). The relative contributions of CD4 +ve and CD8 +ve T cells to 
rejection in different models may depend on the degree of dependence of CD8 +ve 
T cells on CD4 +ve T cells for help (250), the type of graft, the nature of the differences 
between donor and recipient MHC and the sensitisation state of the recipient (251).
A further possible rejection mechanism identified in rodents involves the presentation of 
processed allogeneic class I MHC molecules by host APC to CD4 +ve T cells, which 
then provide help to B cells for alloantibody production (252).
Graft-infiltrating lymphocytes cultured from endomyocardial biopsies have provided 
evidence for a role for CTL in the acute rejection of human cardiac allografts (253). 
Donor-specific CTL can be present in rejection-free allografts (254, 255). However, 
higher frequencies of donor-specific CTL were found in graft-infiltrating lymphocytes 
from patients who had rejection episodes compared to those without rejection (256,
39
257). Moreover, graft-infiltrating committed CTL with high avidity for donor HLA class 
I and class II antigens were present during rejection episodes, whereas in the absence of 
rejection low avidity cells predominated (235, 258). The differences in avidity of CTL 
may thus explain why alloreactive CTL can be present in grafts without histological 
rejection (258). Graft-infiltrating lymphocytes have also been shown to lyse donor heart 
endothelial cells (259), although the ability of CTL to directly injure myocytes is not 
proven (260, 261). The expression of perforin and granzymes in graft-infiltrating 
lymphocytes is also associated with rejection and provides further evidence for a direct 
role of CTL (209,210).
2.1.9. Immunosuppression.
In clinical transplantation the administration of drugs which suppress the recipient’s 
immune system is necessary to prevent allograft rejection. Different combinations of 
dmgs have been used at different centres, but triple therapy with CsA, azathioprine and 
corticosteroids has been common in the 1980s and 1990s (262). These drugs formed the 
basis of the immunosuppression given to patients in the present study.
CsA, azathioprine and steroids act in complementary ways to suppress allograft 
rejection. CsA inhibits T cell activation by blocking signal transduction pathways 
involved in the expression of the IL-2 gene. It does this by blocking the action of 
calcineurin (263). CsA binds to the cytoplasmic protein cyclophilin, an isomerase 
involved in protein folding. The CsA-cyclophilin complex then binds active calcineurin
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and inhibits its activity, preventing the dephosphoiylation of cytoplasmic NF-AT and its 
translocation to the nucleus, where it is required for gene transcription.
An alternative mechanism of CsA action has been proposed, based on the obseiwation 
that CsA stimulates the production of transforming growth factor (TGF)-p, a cytokine 
with immunosuppressive activity (264). This effect is mediated by TGF-p-dependent 
induction of the cell cycle inhibitor p21 (265).
Azathioprine is metabolised into the purine analogue mercaptopurine which intercalates 
into a cell’s DNA. It inhibits de novo purine synthesis, the synthesis of DNA and RNA, 
and can create breaks in chromosomal DNA (266). Azathioprine is more active on 
metabolically active cells, and particularly on replicating cells, whose proliferation is 
thereby inhibited (267)
Steroids used in transplantation include methylprednisolone, which is given 
intravenously, and the oral preparations of prednisone and prednisolone. Their 
immunosuppressive action involves several mechanisms, including a potent anti­
inflammatory effect, and the inhibition of macrophage function and T lymphocyte 
activation (266). Steroids are bound by receptor molecules in the cytoplasm and 
transported to the nucleus (268). There, the steroid-receptor complexes bind to 
glucocorticoid response element sites in the promoter regions of specific genes and 
regulate gene transcription (269). Steroids inhibit the secretion of lymphokines and 
inflammatory mediators by macrophages (266), and also directly inhibit T cell activation 
by blocking IL-2 gene expression and signal transduction through the EL-2 receptor 
(270, 271).
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Antibodies directed towards lymphocytes or to specific lymphocyte antigens have also 
been used for immunosuppression after transplantation. Polyclonal antisera are produced 
by immunising animals such as rabbits, goats or horses with human lymphocytes derived 
from lymph nodes, yielding anti-lymphocyte globulin (ALG), or with thymus gland 
lymphocytes, yielding anti-thymocyte globulin (ATG) (266). Monoclonal antibodies to 
specific T cell markers such as CD3 (known as 0KT3) have also been used in attempts 
to selectively manipulate the immune response to the allograft (272).
Polyclonal anti-thymocyte globulin contains antibodies specific for numerous T cell- 
specific and non-T cell specific cell-surface molecules (273). Anti-lymphocyte serum 
was historically thought to selectively deplete circulating lymphocytes by complement- 
mediated lysis and opsonisation and phagocytosis in the liver (274 - 276). More 
recently, it has been proposed that the mechanism of ATG-mediated suppression could 
also involve the engagement of multiple T cell surface receptors resulting in partial 
activation and anergy (273, 277, 278). The immune response to an allograft regenerates 
after treatment with anti-lymphocyte serum (279, 280), but lymphocyte subsets can be 
altered for extended periods. Decreased CD4 ; CD8 ratios were seen for up to five years 
in anti-thymocyte globulin treated renal transplant recipients as a result of depletion of 
CD4 +ve T cells and increased repopulation of CDS +ve T cells (281).
Anti-lymphocyte antibodies have been used as induction therapy given for a short period 
immediately after transplantation to prevent early rejection (282), and for the treatment 
of acute rejection episodes (283). Some patients in the present study received induction 
immunosuppression with ATG as part of a study of the effectiveness of this agent.
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2.1.10. Transplantation tolerance.
Transplantation tolerance has been defined as “the indefinite survival of a graft in the 
absence of ongoing immunosuppression” (284). This state has been achieved 
experimentally in animals (285, 286) and has been demonstrated in a small number of 
human transplant recipients (287, 288).
Several different mechanisms may contribute to the induction and maintenance of 
transplantation tolerance. Potential mechanisms include the deletion of developing 
T cells by the introduction of allogeneic cells or peptides to the thymus; the deletion of 
T cells in the periphery; the induction of immunological ignorance by blocking 
costimulation; T cell anergy; and T cell-mediated suppression (289).
The survival of solid organ allografts with continued immunosuppression has sometimes 
been called “graft acceptance” or “operational tolerance” (290, 291), although the 
distinction between tolerance and acceptance is not always made.
Human transplant recipients initially require intense immunosuppression to prevent 
rejection, but doses are reduced after the first few weeks and, in the longer term, 
individual components such as steroids are sometimes stopped completely (292). Many 
studies have shown reduced cellular immune responses of patients towards their donors 
after transplantation (293). It is apparent, therefore, that some form of adaptation of the 
recipient’s immune system to the graft can occur in immunosuppressed patients.
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Reduced immune reactivity to the donor is also sometimes referred to as tolerance (294, 
295). It is perhaps more accurate, however, to refer to this as hyporeactivity or 
unresponsiveness of the particular cell or process studied, since in most cases 
immunosuppression is not withdrawn to determine if “tme” transplantation tolerance has 
developed.
2.2. Cellular assays of direct allorecognition.
2.2.1. Mixed lymphocyte culture.
When lymphocytes from two unrelated individuals are cultured together in vitro some of 
the cells are transformed into proliferating lymphoblasts (296, 297). Proliferation in 
MLC is stimulated mainly by differences in the HLA class II region (112, 298), The 
degree of proliferation is related to the degree of mismatching for HLA class II antigens 
between the individuals tested (299 - 301).
The MLC was first used as a cellular compatibility test before living related renal 
transplantation (302, 303), and has since been used to monitor immunological reactivity 
between patient and donor after solid organ transplantation. In several studies reduced 
donor-specific responses (“hyporesponsiveness”) in MLC were found in some organ 
allograft recipients (292, 304 - 308) and in some studies this was associated with the 
absence of rejection or a reduced incidence of rejection (292, 305 - 308).
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2.2.2. Cell-mediated lympholysis.
Some of the lymphocytes which proliferate in MLC are cytotoxic to cells of the 
stimulator (309). These cytotoxic lymphocytes are predominantly directed towards class 
I MHC molecules, although class Il-specific CTL can also occur, but class II differences 
are necessaiy for T cell proliferation and the generation of cytotoxicity (113, 310). Cell- 
mediated lympholysis (CML) can be assayed quantitatively by measuring the cytotoxicity 
of MLC-generated effector cells at defined effector to target cell ratios (311).
CML assays have also been used for immunological monitoring after transplantation, 
and were found by some investigators to correspond better to clinical events than MLC 
(312-314). More transplant recipients are hyporesponsive to donor antigens by the 
CML assay than by the MLC assay (313,315,316) and hyporesponsiveness is found 
more consistently by CML than by MLC, in which responses appear to vaiy (317-319). 
Overall, donor-specific hyporeactivity is found in about 70 % of recipients by the CML 
assay, and in about 30 % of recipients by the MLC assay (293).
Although CML hyporesponsiveness is frequently observed after transplantation, the 
clinical value of the CML assay is uncertain. In a large study CML non-responsiveness 
had only limited predictive value for graft survival, moreover rejection occurred in some 
patients who were non-responsive in the CML assay (320).
CML hyporesponsiveness may theoretically occur as a result of hyporesponsiveness of 
either CD8 +ve or CD4 +ve T cells, which could explain the higher prevalence of 
hyporesponsiveness by CML compared to MLC. However, CML reactivity has been
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reported despite reduced MLC responses (313), so there may be other reasons for the 
different prevalences of hyporesponsiveness. It has been suggested that MLC reactivity 
could be stimulated by indirect as well as by direct presentation pathways, whereas 
cytotoxic T cells mainly recognise targets directly (293), but there is conflicting evidence 
regarding MLC stimulation by the indirect pathway after transplantation (321, 322). 
Different regulatoiy mechanisms may also function in MLC and CML responses. The 
involvement of suppressor cells in CML hyporesponsiveness has been proposed in 
several reports (317, 319, 323),
2.2.3. Limiting dilution analysis of T lymphocytes.
Frequencies of T lymphocyte precursors in various mixed cell populations can be 
estimated by the technique of limiting dilution analysis (LDA) (15). Limiting dilution 
assays are quantitative, and are thus more informative than semi-quantitative assays such 
as MLC and CML. LDA has, to a large extent, replaced MLC and CML assays in post­
transplant monitoring, and has provided a more detailed analysis of the relationship 
between helper and cytotoxic T cell subsets after transplantation.
Limiting dilution assays have been applied to the study of CTLp in bone marrow and 
solid organ transplantation (18, 19, 324), and allospecific T cell repertoires (325, 326). 
Limiting dilution analysis has also been used to quantify helper T lymphocyte sub­
populations, including precursors of IL-2 producing cells (referred to as the helper T 
lymphocyte precursor assay, HTLp) (327) and precursors of cells which produce other 
cytokines, such as EL-4 (328).
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In limiting dilution assays cells from the test population are cultured in replicate in a 
series of dilutions together with defined stimulator cells. Culture conditions are optimal 
for the proliferation of the precursor cell being studied. After a period of incubation to 
allow the precursor cells to proliferate, the proportion of cultures at each dilution which 
received the precursor cell of interest are determined by assaying effector flinction in 
each replicate culture (329).
Poisson probability statistics are applied to these data to provide an estimate of the 
frequency of the precursor cell in the original population (330). When cells ft om a 
homogeneous cell suspension are distributed between culture wells in identical volumes, 
the number of precursor cells in individual replicate cultures varies due to random 
distribution with a probability described by the Poisson distribution. Interpretation of 
limiting dilution assays is based on the fraction of replicate wells at each dilution which 
are negative for effector function, because these are known to have received no 
precursor cells, whereas the number of precursors received by a positive well is not 
known. A minimum of 20 replicates are required at each dilution to give reliable 
frequency estimates (330).
The proportion of negative wells at each dilution is represented by the zero term of the 
Poisson distribution, which predicts that 37 % of culture wells will be negative when 
there is an average of one precursor cell per well (329). Each dilution of the original 
population yields a different fraction of negative cultures. Different statistical treatments 
of the data to give the frequency estimate have been used, including least squares fitting 
(329) and minimum chi square methods (331), but the maximum likelihood method is
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widely accepted as the procedure of choice (330, 332). Maximum likelihood estimation 
is a complex, iterative procedure, which is usually performed by calculator or computer.
For the frequency estimate to be valid, the assay conditions should be such that the 
precursor cell type whose frequency is being estimated is the only limiting factor in the 
culture system, and a single precursor cell should be able to generate a detectable 
response. This is known as the single hit model (330). Conformity to single-hit kinetics 
is tested for each assay by generating a chi  ^goodness-of-fit statistic and determining the 
corresponding p value.
The frequency of allospecific CTLp is determined by culturing the test population with 
allogeneic stimulator cells in the presence of interleukin-2. Lysis of stimulator-type 
target cells after 7 to 10 days of culture indicates that one or more CTL precursors were 
present in a culture well (17).
The ability of eveiy human T cell to undergo clonal expansion under appropriate culture 
conditions was demonstrated using a limiting dilution assay in which human peripheral 
blood T cells were cultured in medium containing T cell growth factor (TCGF) and 
PHA, which activates most T cells (333). Most of the CTLp in peripheral blood belong 
to the CDS +ve T cell subset and are HLA class I restricted (16, 334). However, high 
frequencies of class Il-speclfic CTL are found in CD4 +ve enriched populations (335). 
Alloreactive CTLp can be specific for mismatches at the HLA-A, -B and -Cw loci (336 - 
339) and can also recognise subtypes of HLA class I antigens (340,341). CTL specific 
for the public HLA class I determinants Bw4 and Bw6 are not detected (337, 342). 
CTLp specific for minor histocompatibility antigens are present at very low frequencies
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in unsensitised individuals (343, 344), but can be detected at high frequencies after in 
vivo sensitisation (345, 346). CTLp frequencies between HLA~identical siblings are very 
low (less than 5 per million peripheral blood mononuclear cells (MNC)) or undetectable 
(347, 344). Those few precursors that do react in HLA-identical combinations may be 
specific for mismatched minor histocompatibility antigens.
2.2.4. CTLp assay methods.
Different methods have been used for limiting dilution analysis of CTLp (15). The 
addition of a source of TCGF was shown to be essential in all methods (16, 17, 325). In 
earlier studies supernatant from PHA-stimulated cells or MLC was used for this purpose 
(16, 325, 333), but it was later shown that IL-2 is the only lymphokine necessary for the 
expansion of alloreactive CTLp (17). Interleukin-4 (IL-4) did not increase the CTLp 
frequency and interleukin-1 was inhibitoiy. Moretta et al. found the highest clonal 
efficiency when TCGF was added after two days of culture, and Kaminski et al. found 
that the addition of low concentrations (5 units/ml) of IL-2 on days three and six gave 
optimal CTLp frequency without non-specificity (17,333). The use of filler cells was 
shown to be unnecessary (17).
CTLp frequencies have been determined in populations of peripheral blood MNC and
T cells purified by positive (16, 333) and negative (335) selection methods. Cells used as 
stimulators in the CTLp assay have included peripheral blood MNC, spleen MNC and 
Epstein Barr virus (EBV)-transformed B cell lines. B cell lines are stronger stimulator
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cells than peripheral blood MNC, but also induce high levels of non-specific reactivity 
(348).
Mitogen-stimulated T cell blasts are commonly used targets for cytotoxic activity in the 
CTLp assay, although some researchers have preferred EBV-transformed B cell lines or 
unstimulated peripheral blood MNC (337, 348). Higher frequencies of specific 
alloreactive CTLp are detected after ten days of culture than after six or seven days of 
culture, especially in combinations which give rise to low CTLp frequencies (16, 17).
The CTLp assay methods referred to above do not distinguish between in vivo activated 
CTL, naive CTL precursors or memory cells. CTL of all these activation states which 
can proliferate and develop effector function in vitro are detected. In vivo activated, 
committed CTL can be distinguished from naive CTLp by their ability to grow in culture 
with IL-2 in the absence of allogeneic stimulator cells (349). Other modifications to the 
CTLp assay permit the identification of CTL with differing avidity for target cells, based 
on the susceptibility to inhibition by anti-CD4 or anti-CD8 antibodies (258, 350), or the 
identification of CTL with differing susceptibility to immunosuppressive dmgs (351, 
352). In this context, avidity is defined as the overall strength of binding between a 
T cell and an APC or target cell, and reflects the interactions between T cell receptors 
and antigenic peptide-MHC complexes, and between CD4, CDS and other accessory 
molecules and their ligands (235, 353).
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2.2.5. The contribution of natural killer cell-like activity to estimates of CTLp frequency.
For the CTLp frequency estimate to be accurate, the cytotoxicity measured in the assay 
should be mediated by CDS +ve or CD4 +ve CTL which specifically recognise HLA 
class I or class II molecules on the surface of the target cells. Other forms of 
cytotoxicity, such as NK cell-like activity and LAK activity, which are not MHC 
restricted, have been found after MLC (354, 355) and could influence CTLp frequency 
estimates if cytotoxic to allogeneic targets.
LAK activity can be induced in vitro by high concentrations of IL-2 (greater than 1 nM 
or 30 International Units) (356). An IL-2 concentration of 5 units/ml was found to give 
minimal non-specific reactivity against autologous targets in the CTLp assay (17). The 
absence of lymphokine-induced non-specificity in the CTLp assay at low IL-2 
concentrations has been further demonstrated by the absence of lysis of 3’^* party or 
autologous targets in split-well assays (16, 325).
It has been suggested in several studies that NK-like activity is distinct from alloreactive 
cytotoxicity in MLC and in CTLp assay cultures. Allogeneic lymphocytes and K562 
cells did not cross-compete as targets in cold-target competition assays with MLC- 
generated cytotoxicity (355, 357). In an HLA class Il-specific CTLp assay, the depletion 
of CD56 +ve cells before culture did not affect the frequencies found, or specific lysis of 
allogeneic B lymphoblastoid cell line targets (335). Furthermore, cell-sorter purified 
CDS +ve, CD 16 -ve T cells and CD 16 +ve, CD3 ~ve NK cells cultured in limiting 
dilution with exogenous IL-2 were specific for allogeneic lymphoblasts or K562 cells 
respectively, with very little cross-reactivity (358). There is, however, at least one report
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in which the depletion of CD56 +ve cells resulted in lower CTLp frequencies in two of 
three cases (359).
NK cells appear to have a repertoire of killing for allogeneic specificities (360, 361). 
Susceptibility of the target to lysis depends upon both the nature of the HLA mismatch 
between the responder and stimulator cells and the repertoire of inhibitory receptors 
expressed by the responder’s NK cells (362, 363). Populations of NK cells generated 
after the culture of certain combinations of allogeneic lymphocytes can specifically lyse 
stimulator-derived T cell blasts (364, 365).
The involvement of NK-like activity in the CTLp assay was investigated in the present 
study using the K562 cell line. K562 is a haematopoietic tumour cell line which does not 
express HLA class I molecules and is a highly sensitive target for NK cell activity (75). 
Firstly, the K562 cell line was used as a target in split-well assays to assess the extent of 
NK-like activity in CTLp assay cultures. Then cold target competition assays were used 
to determine if K562 cells could inhibit lysis of specific allogeneic targets, and 
conversely, if allogeneic cells could inhibit lysis of K562 targets. Five different 
responder-stimulator combinations were tested in each case, using splenic stimulator 
cells and peripheral blood mononuclear responder cells, as used in the subsequent assays 
of cardiac transplant patients. Inhibition of cytotoxicity would suggest the involvement 
of NK-like activity in the lysis of allogeneic target cells and a possible contribution to 
CTLp frequency estimates.
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2.3, The use of cellular assays of direct allorecognition for immunological 
monitoring after cardiac transplantation.
There are many reports of the use of cellular assays of peripheral blood lymphocytes for 
immunological monitoring after renal transplantation (293, 366), but fewer reports have 
been published relating to cardiac transplantation. Reinsmoen et al. found donor 
antigen-specific hyporesponsiveness in 6 of 27 cardiac transplant recipients using MLC. 
Hyporesponsiveness was associated with the absence of chronic rejection in these 
patients (308). However, van Besouw et al. found no differences in MLC or in 
frequencies of helper T lymphocytes between patients with and without chronic rejection, 
but found higher reactivity to a non-specific stimulus in patients with chronic rejection 
(367). Different stimulator cells were used in the two studies: Reinsmoen et al. used 
homozygous typing cells which shared HLA antigens with the donor, whereas Van 
Besouw et al. used transformed B cell lines from the donor. Van Besouw et al. also 
found comparable MLC responses before and after transplantation, independent of acute 
rejection (321). Wijngaard et al. reported CML nonreactivity to donor cells in 7 of 10 
cardiac recipients in the first three years after transplantation, coincident with the absence 
of acute rejection (294).
Some investigators used limiting dilution assays of CTLp to examine donor-specific 
responses. Reader et al. found higher CTLp frequencies in samples taken during biopsy- 
diagnosed rejection than in samples taken in the absence of rejection, and some 
correspondence of CTLp frequencies with clinical events after transplantation (368).
Hu et al. reported an overall donor-specific decrease in CTLp frequency within one year 
of transplantation, with individual patients showing different variations in frequency with
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time (19). Whereas Hu et al. found that pre-transplant donor-specific CTLp frequencies 
correlated with rejection, Reader et al. did not. In contrast to the study of Hu et al., 
Loonen et al. found no differences between CTLp frequencies in samples taken before 
and up to three years after transplantation (369). However, the same group found that 
CTLp with high avidity for donor cells were associated with rejection (370).
Peripheral blood HTLp frequencies have also been studied after cardiac transplantation. 
Increases in donor-reactive HTLp frequencies have been reported during rejection 
episodes (370, 371), and decreased HTLp frequencies were found one year after 
transplantation in patients who tolerated steroid withdrawal (372). Cattell et al. found 
decreased HTL frequencies in three of four cardiac recipients, and an increased 
frequency in one patient after rejection (373). Hornick et al. reported donor-specific 
hyporesponsiveness of helper T lymphocytes in five of ten cardiac recipients with chronic 
rejection, four of whom also had low frequencies of donor-specific cytotoxic 
T lymphocytes (374).
The limiting dilution assay methods used by these investigators varied. Differences in the 
concentrations of IL-2 added in the CTLp assays, in the timings of the addition of EL-2, 
and in the duration of culture make direct comparisons difficult. Different patient 
groups, immunosuppression regimens and the use of other treatments such as pre­
transplant blood transfusions may also have contributed to the different results. The 
frequency of sampling and length of follow-up after transplantation also varied between 
the studies. Some studies attempted to correlate CTLp frequencies with acute rejection, 
which is most common in the first months after transplantation, and results from these 
studies might be expected to differ from those which looked for evidence of longer-term
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graft acceptance. With the exception of the study of Hu et al., serial changes in CTLp 
frequency were not reported for most patients. There is wide variation in the CTLp 
repertoire of different individuals towards mismatched HLA antigens (325), so it may be 
more informative to study serial changes in individual patients than to compare groups of 
frequencies at various time points.
The value of assays of peripheral blood CTLp in clinical cardiac transplantation is, 
therefore, uncertain. One reason for a lack of correspondence with rejection could be 
that lymphocytes in the peripheral blood may not reflect those within the graft (370). 
Frequencies of donor-specific CTLp (375) and committed CTL (376) are higher in graft 
infiltrating cells than from peripheral blood. Another possible explanation is that most 
studies have measured direct recognition of donor antigen presenting cells, which ignores 
the recent suggestion that that indirect allorecognition may also be involved in acute and 
chronic rejection of cardiac grafts (377, 378).
However, as already indicated, donor-specific hyporesponsiveness of peripheral blood 
lymphocytes was reported in some studies (19, 294, 308, 372 - 374) and is an established 
phenomenon in some recipients of other solid organ transplants (18, 293, 379, 380). 
Limiting dilution analysis of lymphocyte populations in cardiac transplant recipients 
could therefore be useful in the identification of patients who develop immunological 
hyporesponsiveness towards their graft (293), and assist in the elucidation of mechanisms 
of immunological acceptance of allografts (288, 381). Patients so identified as 
hyporesponsive to donor antigens could be candidates for the reduction of 
immuno suppression, thus minimising the increased risks of malignancy, infections and
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other complications of immunosuppressive therapy which are found in transplant 
recipients (382),
The development of donor-specific hyporesponsiveness after cardiac transplantation was 
investigated in the present study by measuring donor- and 3“* party-reactive CTLp 
frequencies in peripheral blood samples from 15 patients. The sampling was designed to 
allow the comparison of pre-transplant CTLp frequencies with CTLp frequencies at two 
time points in the first year after transplantation. CTLp frequencies were also analysed 
for associations with EMB-diagnosed rejection, induction immunosuppression with 
ATG, and HLA mismatching between recipient and donor.
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3. Aims.
The aims of this thesis were as follows. Firstly, to compare the Matrix 96 Direct Beta 
Counter with a gamma counter for measuring ^^Cr-release in cell culture supernatants, 
with regard to ease of use and rapidity for counting large assays, and to define a protocol 
for the application of the Matrix 96 to assays of clinical samples. Secondly, to apply the 
derived protocol to the clinically relevant question of cardiac allograft rejection and its 
monitoring by means of CTLp frequency analysis. Subsidiaiy objectives were, firstly, to 
identify and quantify the contribution of NK-like activity to CTLp frequency analysis in 
order to determine the specificity of the assay. Secondly, to use the Matrix 96 to 
measure ^^Cr-release from CTLp assays of samples taken from human cardiac transplant 
recipients before transplantation and on two occasions after transplantation. And finally, 
to analyse the CTLp frequencies obtained from cardiac transplant recipients for evidence 
of donor-specific immunological hyporesponsiveness and associations with acute cellular 
rejection.
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METHODS
1. Reagents.
AB serum (heat inactivated, group AB serum from untransfused male donors; Quest 
Biomedical, Knowle, England).
Acetic acid (BDH Laboratory Supplies, Poole, England).
^^Cr (sodium chromate in sodium chloride soln., 7.4-18.5 GBq/mg Cr,
0.37-1.3 GBq/ml, order no. CJS4; Amersham Pharmacia Biotech UK Ltd., Little 
Chalfont, England).
Crystal violet dye (Sigma-Aldrich Co. Ltd., Poole, England).
Dimethyl sulphoxide (DMSO; BDH Laboratory Supplies, Poole, England).
Eosin-Y (Sigma-Aldrich Co. Ltd., Poole, England).
Foetal bovine serum (FBS; Life Technologies Ltd., Paisley, Scotland).
L-glutamine (Life Technologies Ltd., Paisley, Scotland).
Hanks’ balanced salt solution (HBSS; Sigma-Aldrich Co. Ltd., Poole, England). 
Hydrochloric acid (HCl; BDH Laboratoiy Supplies, Poole, England).
IL-2 (human, recombinant {E.coU)\ Boehringer Mannheim UK, Lewes, England). 
Medium 199 (with Earle’s salts, 100 mg/1 L-glutamine and 5.96g/l HEPES; Life 
Technologies Ltd., Paisley, Scotland).
Benzylpenicillin sodium BP (Britannia Pharmaceuticals Ltd., Redhill, England). 
Phytohaemagglutinin (PHA; Cat. no. HA16, Murex Biotech Ltd., Hartford, England). 
Polysucrose/sodium diatrizoate solution (density 1.077; Histopaque-1077, Sigma-Aldrich 
Co. Ltd., Poole, England).
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RPMI 1640 medium with sodium bicarbonate buffering (2 g/1 NaHCOs, pH 7.0-7.4, Life 
Technologies Ltd., Paisley, Scotland).
Sodium chloride, 0.9 % (Baxter Healthcare Ltd., Thetford, England).
Sodium heparin (Leo Laboratories, Princes Risborough, England).
Streptomycin sulphate BP (Evans Medical Ltd., Leatherhead, England).
Triton X-100 (BDH Laboratoiy Supplies, Poole, England).
Zapoglobin (Coulter Electronics Ltd., Luton, England).
The K562 cell line was a kind gift from Ms. A. Galvin, Dept, of Immunology, Queen’s 
Medical Centre, Nottingham.
2. Media used for cell culture and washing.
Cell washing medium consisted of HBSS containing 100 units/ml penicillin and 
100 pg/ml streptomycin.
Complete culture medium (CCM) consisted of RPMI 1640 medium, supplemented with 
10 % vol/vol AB serum, 292 mg/1 L-glutamine, 100 units/ml penicillin and 100 pg/ml 
streptomycin.
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3. Equipment and disposables.
Caesium 137 source (Gammacell irradiator, Molsgaard Medical).
Coulter DN counter (Coulter Electronics Ltd., Luton, England).
Cell culture plates, 24 well, flat bottom (Corning, Bibby-Sterilin, Stone, England).
Cell culture plates, 96 well, U-bottom (Costar UK Ltd., High Wycombe, England). 
Cryogenic vials, sterile (LIP Ltd., Shipley, England).
Gamma counter (Packard Auto-Gamma 5650 gamma counter, Packard Instrument Co., 
Meriden, CT, USA).
Humidified incubator (RS Biotech, Finedon, England).
Matrix 96 Direct Beta Counter (Packard Instmment Co., Meriden, CT, USA).
Nalgene Cryo 1°C freezing container (McQuilkin & Co., Glasgow, Scotland).
Nylon fibre (3 denier, 3.81 cm, type 200; Fenwall Laboratories, Deerfield, Illinois, USA). 
SpotWell-96 metal plate (Canberra Packard, Pangbourne, England).
25 cm^ tissue culture flasks (Corning, New York, USA).
0.75 ml tubes (Luckham LP2, Life Sciences International, Basingstoke, England).
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4. Cell preparation and ci’yopreservation.
Mononuclear cells from human peripheral blood and spleen were required in the 
subsequently described assays and were prepared as follows. Peripheral blood MNC 
were aseptically separated by density gradient centrifugation over poly sucrose/sodium 
diatrizoate solution, then were washed once at 250 g for 15 min, then twice at 400 g for 
5 min in washing medium. Spleen cells were aseptically recovered into washing medium 
by teasing apart the spleen tissue using forceps. Stromal elements were separated from 
the cell suspension by passing the mixture through a syringe containing loosely packed 
nylon fibre, which had previously been primed with 0.5 ml each of FBS and washing 
medium. The cells were collected and washed at 400 g for 5 min, then were resuspended 
in washing medium. MNC then were separated by density gradient centrifugation over 
polysucrose/sodium diatrizoate solution as described above.
Peripheral blood and spleen MNC were frozen in sterile ciyogenic vials at a 
concentration of 10 to 20 x 10® cells/ml, in a mixture consisting of equal proportions of 
FBS and 20 % vol/vol DMSO in 0.9 % sodium chloride. The vials were frozen in a 
Nalgene Cryo 1°C freezing container overnight in a -70°C freezer, then were stored in 
the vapour phase of liquid nitrogen until required.
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5. Determination of cell concentration and viability.
Cell concentrations were determined either by an automated method (Coulter DN 
counter) or manually. For manual counting the cell suspension was diluted with an equal 
volume of 2 % vol/vol aqueous acetic acid, coloured pale violet with crystal violet dye, 
and counted in an Improved Neubauer counting chamber. All cell concentrations for a 
specific patient’s CTLp assays were quantified in the same way to eliminate inter-method 
variability. Cell viability was assessed by exclusion of the vital dye, Eosin-Y, and cells 
were used in the CTLp assay only if their viability was 90 % or greater. ^^Cr-labelled 
PHA stimulated blast cells were counted manually as described above, but using 
undiluted cell suspensions.
6. Preparation of ^ ^Cr-labelled PHA blasts.
Frozen cells were removed from liquid nitrogen and thawed rapidly in a water bath at 
37°C, then were added to 15 ml tubes containing 1 ml each of RPMI 1640 and AB 
seiTim. RPMI 1640 was slowly added to each tube to a volume of 10 ml. The cells were 
pelleted by centrifuging at 300 g for 5 min, then were washed twice in RPMI 1640 and 
resuspended in CCM.
1x10® cells in 1 ml of CCM were added to duplicate wells of 24 well, flat bottomed 
culture plates. PHA was added to each well at 2 pg/ml. The plates were placed in a 
humidified incubator at 37°C with 5 % CO2  in air for 10 days. On days three and seven
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the PHA blast cultures were split and supplemented with CCM containing 10 % vol/vol 
IL-2 to maintain a concentration range of 10® to 10® cells/ml.
The PHA blast cultures were harvested and washed twice in RPMI 1640. 1 x 10  ^cells 
of each type were resuspended in 200 pi of CCM and labelled with 7.4 MBq of ®^ Cr at 
37°C for 90 min. The ®^ Cr labelled cells were washed three times with RPMI 1640, then 
were resuspended in CCM and were counted manually.
7. Assessment of the Matrix 96 Direct Beta Counter.
7.1. Determination of counting time for the Matrix 96 Direct Beta Counter.
®^Cr-labelled PHA blast cells were prepared from spleen mononuclear cells from a single 
donor as described above. A series of dilutions of the labelled cells (10000, 8000, 6000, 
4000, 2000 and 1000 cells per well; 16 wells per dilution) were added to a 96 well, Li- 
bottom cell culture plate and the cells were lysed by the addition of 100 pi of 1 % vol/vol 
Triton X-100 in water followed by incubation at 37°C for 4 hours. The plate was 
centrifuged at 250 g for 5 min. 100 pi of the supernatant from each well was transferred 
using a multi-channel pipette to 0.75 ml tubes for counting with a gamma counter, then 
50 pi was transferred to the corresponding positions of a SpotWell-96 metal plate for 
counting with the Matrix 96 Direct Beta Counter. The 0.75 ml tubes were sealed with 
wax and stored at room temperature overnight. The SpotWell-96 plate was placed in a 
fume cupboard overnight at room temperature to allow drying to completion.
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The 0.75 ml tubes were counted once, to obtain counts per min (cpm). Samples were 
counted in sequence to allow direct comparison with the counts obtained from the same 
wells by the Matrix 96. Observation of real-time counts of the SpotWell-96 plate 
indicated that counts of 17 to 19 min gave results closest to the gamma counter cpm.
The SpotWell-96 plate was therefore counted for 17, 18 and 19 min and these counts 
were used for detailed analysis.
The experiment was repeated, vai*ying the labelled cell concentration to 1000, 800, 600, 
400, 200 and 100 cells per well to assess responsiveness at a lower range of counts. The
0.75 ml tubes were counted once, to obtain cpm. The Spotwell-96 plate was counted for 
18 and 19 min, the times which were found in the first experiment to give counts closest 
to the gamma counter cpm.
7.2. Comparison of the Matrix 96 with a gamma counter.
Lysates from ®^Cr-labelled PHA blasts from a single donor were prepared as above, using 
blast cell dilutions of 1000, 800, 600, 400, 200 and 100 cells per well, with 16 replicates 
at each dilution. The 0.75 ml tubes were counted three times, in sequence, using a 
gamma counter, to obtain cpm. The SpotWell-96 plate was counted three times using 
the Matrix 96, each time for 19 min.
The counting methods were compared using an analysis of differences between the 
values obtained by each method (14). Limits of agreement between two sets of counts 
were given by the mean of the differences between the counting methods plus and minus
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two standard deviations. The 95 % confidence inteiwals for the upper and lower limits of 
agreement were calculated as described. The limits of agreement of the Matrix 96 and 
gamma counter were calculated using two repeated sets of measurements for each 
counter. Variation in repeated measurements (“repeatability”) was assessed by the co­
efficient of repeatability, calculated as twice the standard deviation of differences 
between pairs of repeated measurements.
The counters were not compared directly for counting CTLp assays because the volume 
of supernatant required (150 pi) could not be taken without also taking up unlysed cells. 
This was avoided by the use of detergent-lysed preparations in the experiments described 
above.
8. The Cytotoxic T lymphocyte Precursor Assay.
The method of Kaminski et al. was used for all CTLp assays (17). Aseptic technique 
was used for all stages except the ®^Cr-release assay.
8.1. Limiting dilution cultures.
Frozen cells were thawed as described above. Stimulator cells were irradiated with 
30 Gy from a Caesium 137 source.
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The limiting dilution cultures were set up as follows. Eight dilutions of the responder 
cell population (usually 4, 3, 2, 1, 0.5, 0.25, 0.125 and 0.0625 x 10"^  cells per well,
24 wells per dilution) were added in 50 pi volumes to 96 well, U-bottom cell culture 
plates. 5 X 10"^  irradiated stimulator cells were added to each well in a volume of 
100 pi. Control wells consisted of 24 wells of stimulator cells in the absence of 
responders as a baseline control, 8 wells of stimulator cells with unrelated responder 
cells, 8 wells of unrelated stimulators with patient responder cells, 8 wells of stimulators 
with irradiated unrelated responder cells, and 8 wells containing culture medium alone 
for the measurement of spontaneous ®^ Cr release.
The plates were placed in a humidified incubator at 37°C with 5 % CO2  in air for 
10 days. On days thi ee and seven each well of the limiting dilution and control cultures 
was supplemented with IL-2 in 25 pi of CCM, to a final concentration of 5 units/ml IL-2 
per well.
8.2.  ^ Cr-release assay.
®^Cr-labelled PHA blast cells were prepared from each stimulator cell type as described 
above, and the concentration of each was adjusted to 1 x 10® cells/ml. 100 pi of 
supernatant was removed from each well of the assay plates using a multi-channel 
pipette, and the cell pellets were resuspended by pipette in the remaining 100 pi of 
culture medium. 100 pi of the labelled PHA blast cells was then added to each well of
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the assay and control plates (1 x lO'^  cells/well), the target cell added being the same as 
the stimulator cell in the limiting dilution cultures. Total release of ®^ Cr was determined 
by adding 100 pi of each labelled cell to 100 pi of O.IM HCl. All plates were then 
incubated for four hours at 37°C with 5 % CO2
After the four hour incubation, the plates were centrifuged at 250 g for 5 min, then 
50 pi of supernatant from each well was transferred by multi-channel pipette to a 
Spotwell-96 metal plate in the same pattern as in the 96-well culture plates. The 
Spotwell-96 plates were counted for 19 min using the Matrix 96, as previously 
determined to be optimal.
8.3. Calculation of results.
Positive wells were defined as those with counts greater than the mean count plus three 
standard deviations of the 24 wells containing only irradiated stimulators and labelled 
target cells (baseline control). In eight assays where the release from these wells had a 
high standard deviation (mean + 3 SD > 8 % of total release), wells containing labelled 
target cells alone (spontaneous release) were used to determine positiveness. 
Spontaneous release has been used by others to determine positiveness (19) and was 
considered valid here because the use of an erroneously high threshold results in 
underestimation of the CTLp frequency. CTLp frequencies with 95 % confidence 
intervals (95 % Cl) were calculated from the numbers of negative wells at each dilution 
by the maximum likelihood method, using a general linear interactive modelling-based 
computer program (developed at Hammersmith Hospital, London). The chi  ^goodness-
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of-fit value was used to test for single-hit kinetics, that is, that a single factor was 
limiting. Chi^ values with p > 0.05 are usually considered acceptable. Frequency 
estimates were considered to be different if their 95 % confidence intervals did not 
overlap. The control wells were examined to ensure that stimulation and proliferation 
had occurred in the appropriate cell populations. Control wells containing stimulators 
with irradiated unrelated responder cells confirmed the absence of proliferation of 
irradiated cells. Results were displayed graphically by converting the fraction of negative 
cultures at each dilution to its natural logarithm and plotting these against responder cell 
number. If the data conform to single-hit kinetics then such a plot takes the form of a 
straight line through the origin.
9. Assessment of natural killer-like activity in the CTLp assay.
9.1. Culture of the K562 cell line.
The K562 cell line was cultured in medium consisting of RPMI 1640 supplemented with 
10 % vol/vol FBS, 292 mg/1 L-glutamine, 100 units/ml penicillin and 100 pg/ml 
streptomycin. K562 cells were stored in liquid nitrogen at a concentration of 
4x10® cells/ml in the freezing mixture described above. Four days before needed as 
targets, frozen cells were removed from liquid nitrogen and thawed rapidly in a water 
bath at 37°C. Thawed cells were transferred to 15 ml tubes and 10 ml culture medium 
was slowly added to each tube. The cells were pelleted by centrifuging at 300 g for 
5 min, then were resuspended in 10 ml culture medium and the contents of each tube 
were transferred to a 25 cm^ tissue culture flask. The flasks were placed in a humidified
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1
incubator at 37°C with 5 % CO2  in air. On the third day, two volumes of fresh culture 
medium were added and the cultures were split between three 25 cm^ flasks. On the day 
of the ®^ Cr- release assay, K562 cells were washed and labelled as described above for 
PHA blast cells.
9.2. K562-directed cytotoxicity in CTLp assay.
Four CTLp assays were set up as described above. In two of the assays the cultures were 
split into two equal portions on day 10 by transferring 100 pi from each well to the 
corresponding well of a fresh 96 well, U-bottom plate. Cytotoxicity was then measured 
against both the stimulator-type target cell and against K562 (10"^  target cells per well in 
each case). In the other two assays the cultures were only tested against K562 targets 
because stimulator-type target cells were not available in sufficient numbers to carry out 
this assay. The responder and stimulator cells were from HLA-identical siblings in one 
assay and from unrelated individuals in the remaining assays. Peripheral blood MNC 
were from normal individuals and spleen MNC were from cadaver donors. Peripheral 
blood responder cells and splenic stimulator cells were used where possible to be 
consistent with the responder and stimulator cell types used in subsequent assays of 
patient samples.
Spontaneous release of ®^ Cr from K562 targets was obtained by incubating 100 pi of 
labelled cells with 100 pi of culture medium (mean of 24 replicate wells). Total release 
of ®^ Cr was obtained by incubating 100 pi of labelled cells with 100 pi of Zapoglobin
69
(two drops per ml saline; mean of four or eight replicate wells). Test release was the 
mean ®^ Cr release of the 24 replicates at each dilution.
Specific lysis of the K562 targets was calculated using the formula:
Specific lysis = test release - spontaneous release x 100 
total release - spontaneous release
9.3. Determination of target cell ratios for cold target competition experiments.
Cold target competition assays were based on the method of Leclercq ei al. (383).
Due to the large size of limiting dilution assays it was only practical to test cold target 
competition at a single unlabelled : labelled target cell ratio. A preliminary experiment 
was carried out to determine a suitable cell ratio. 96 replicates of 5 x 10"^  splenic 
stimulator cells (HLA-A2, ~A25, -B35, -B57, -Cw4, -Cw6, -DR7, -DR8) were cultured 
with 5 x peripheral blood mononuclear cell responder cells from an unielated 
individual (HLA-A2, -A3, -B7, -B35, -Cw4, DR not tested) for 10 days with the 
addition of 5 units/ml IL-2 on days thi ee and seven. On day 10, 50 pi of the supernatant 
was removed from each well, then the cells were resuspended the remaining volume and 
100 pi of each culture was discarded to simulate the splitting of wells in subsequent 
assays. 50 pi of unlabelled cells were added to appropriate wells to give final
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unlabelled : labelled target ratios of 0, 10:1, 20:1, and 40:1, chosen to cover a wide range 
of values. Eight replicates of each target ratio were set up for each of the following 
combinations:
1. unlabelled K562 : ®^ Cr K562
2. unlabelled stimulator-type targets : ®^ Cr stimulator-type targets
3. unlabelled stimulator-type targets : ®^CrK562
The plate was centrifuged at 80 g for 5 min, then incubated at 37°C for 30 min. 100 pi 
of the appropriate labelled target cells (1000 cells per well) was then added to each well, 
the plate was centrifuged as before, and cytotoxicity was measured in a four hour ®^ Cr
release assay. Percentage inhibition of ®^ Cr release was calculated for each target ratio,
using the mean ®^ Cr release from eight replicates.
9.4. Cold target competition by stimulator-type PHA blasts of killing of K562 
targets.
Five assays were performed to determine if unlabelled stimulator-type target cells could 
inhibit the K562-directed cytotoxicity which developed in the CTLp assay cultures. The 
CTLp assays were carried out as described above. On day 10, 50 pi of the supernatant 
was removed from each well of the cultures, then the contents of each well were 
resuspended and 50 pi was transferred to the corresponding wells of each of two fresh 
sets of 96 well, U-bottom plates. 50 pi of medium was added to two sets of plates and to 
the third set was added 50 pi of unlabelled PHA blast cells (2 x lO'^  cells per well) from
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the stimulator in the CTLp assay (cold competitors). The plates were centrifuged at 80 g 
for 5 min, then incubated at 37°C for 30 min. ®^ Cr K562 targets were added to one set of 
plates without cold competitors (1000 cells per well), and ®^ Cr stimulator targets were 
added to the other (1 x lO'^  cells per well). ®^ Cr labelled K562 targets were added to the 
set of plates with cold competitors (1000 cells per well), giving a competitor : target 
ratio of 20:1. All plates were centrifuged as before, then cytotoxicity was measured in a 
four hour ®^ Cr release assay. Specific lysis was calculated as before.
9.5. Cold target competition by K562 cells of killing of stimulator-type targets.
Five assays were performed to determine if unlabelled K562 cells could inhibit ®^ Cr 
release from labelled stimulator-type target cells and reduce the frequency estimate in 
CTLp assays. The CTLp assays were carried out as described above. On day 10 the 
contents of each well were resuspended and 100 pi was transferred to the corresponding 
well of a fi'esh set of 96 well U-bottom plates. 50 pi of culture medium was added to 
each well of one set of plates, and 50 pi of unlabelled K562 cells was added to the other 
set (4 X 10"^  cells per well). The plates were centrifuged at 80 g for 5 min, then incubated 
at 37°C for 30 min. ®^ Cr stimulator- type target cells were then added to both sets of 
plates (2000 cells per well), the plates were centrifuged as before, and cytotoxicity was 
measured in a four hour ®^ Cr release assay. The competitor : target ratio was 20:1, as 
determined previously. The CTLp frequency was calculated for split-well cultures with 
and without the presence of unlabelled K562 competitors.
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10. Reproducibility of the CTLp assay.
Identical assays were set up on three separate occasions to assess the reproducibility of 
the CTLp assay. Frozen splenic mononuclear cells from a single responder-stimulator 
pair (responder: HLA-A2, -B62, -B27, -Gw3, -Cw6, -DR4, -DQ8; stimulator: HLA-A2, 
-A29, -B35, -B44, Cw4, -DRl, -DR4, -DQl, -DQ7) were thawed on each occasion and 
CTLp assays were carried out as described above. One of the assays was set up in 
duplicate from the same starting cell populations. All assays were counted using a 
gamma counter.
11. Patients.
15 patients who received orthotopic cardiac transplants between January 1994 and July 
1995 were included in this study. 14 other patients transplanted during this period were 
excluded: 5 patients died in the follow-up period (3 of whom died before discharge), and 
samples were inadequate for 9 patients. Of the patients studied, 10 were male and 5 
were female. Age at transplantation ranged from 19 to 59 years (median 54 years). 
Indications for transplantation were: ischaemic heart disease (eight patients), dilated 
cardiomyopathy (six) and valvular heart disease (one). Patient details are shown in 
table 1.
HLA class 1 antigens of patients, donors and control cells were typed using the 
complement-dependent lymphocytotoxicity test, based on the National Institutes of
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Health method (384). Local, national (United Kingdom Transplant Support Services 
Authority), and exchanged HLA typing reagents were used. HLA-DRB1 and -DQB loci 
were typed using the polymerase chain reaction sequence-specific primer method (385, 
386).
Patient Sex
Age at 
transplant (years)
Indication for 
transplantation
ATG
induction
IM F 58 Ischaemic heart disease No
PK F 43 Dilated cardiomyopathy No
SS M 19 Dilated cardiomyopathy Yes
GM F 48 Ischaemic heart disease Yes
RF M 55 Ischaemic heart disease No
JH M 55 Ischaemic heart disease No
GS M 56 Valvular heart disease Yes
WM M 54 Dilated cardiomyopathy Yes
JC F 59 Dilated cardiomyopathy No
TF M 55 Ischaemic heart disease No
GF M 49 Ischaemic heart disease Yes
AM M 33 Dilated cardiomyopathy Yes
TD M 59 Ischaemic heart disease No
WB M 41 Dilated cardiomyopathy Yes
JD F 46 Ischaemic heart disease No
Table 1. Patient characteristics. Patients are listed in chronological order of 
transplantation. ATG induction = patients who received induction immunosuppression 
with anti-thymocyte globulin.
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Pre-transplant semm samples were retrospectively crossmatched against donor T and B 
lymphocytes for each patient, with the exception of patient IM, who was crossmatched 
prospectively. HLA typing and crossmatching were performed by staff of the Tissue 
Typing Laboratory at Glasgow Royal Infirmary.
12. Immunosuppression.
Standard maintenance immunosuppression consisted of CsA (two to three mg/kg pre- 
operatively, then titrated to achieve a whole blood trough level of 600 ng/ml (enzyme 
immuno-assay) by one week post transplant, reduced to a target level of about 250 ng/ml 
by one year post-transplant), azathioprine (three mg/kg pre-operatively, thereafter one to 
two mg/kg/day) and steroids (iv methyl prednisolone peri-operatively, then oral 
prednisolone at one mg/kg/day tapered to 0.2 mg/kg/day at four weeks). Seven of the 
fifteen patients were selected at random to receive cytolytic induction therapy with ATG 
These patients received 500 mg equine ATG (Merieux) intravenously pre-operatively. 
Post-operatively, daily doses were given for seven days, titrated against the daily 
peripheral blood CD2 count to give a count of 100 cells/mm^. The induction group 
received oral prednisolone at 0.5 mg/kg/day for the first two weeks post-transplant, 
reduced thereafter to 0.2 mg/kg/day. CsA was as for the standard group pre-operatively, 
then was titrated to achieve a whole blood trough level of 600 ng/ml by four days post­
transplant. Azathioprine was as for the standard triple immunosuppression group.
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Acute cardiac rejection was diagnosed by endomyocardial biopsy, according to the 
grading system of the International Society of Heart and Lung Transplantation (201). 
Rejection of grade two or above in the first six weeks after transplantation was treated 
with intravenous methylprednisolone (1 g daily for three days). After this period 
rejection episodes were treated by increasing oral prednisolone to 1 mg/kg/day for thiee 
days, then tapering to a maintenance dose over two weeks. One patient (GS) with 
rejection refractory to steroids (more than three pulses of steroid therapy) received 
0K T3. The same patient was ftirther treated with methotrexate after continuing 
rejection. Patient WM also received cyclophosphamide.
13. Patient sampling.
Peripheral blood samples were taken from each patient immediately before the transplant 
operation (T l) and between 3 and 7 months (79 to 200 days, median 104; T2) and 9 and 
15 months (257 to 455 days, median 301; T3) after transplantation. At each sampling 
point 50 to 80 ml of venous blood from each patient was collected into an equal volume 
of Medium 199 containing 20 units/ml sodium heparin, 100 units/ml penicillin and 
100 pg/ml streptomycin. The diluted blood was kept in a 22°C incubator until processed 
(usually within 24 hours).
A portion of spleen was collected from the cardiac donor at the time of organ retrieval. 
The spleen was stored in Medium 199 at 4°C for no more than 48 hours before 
processing.
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14. CTLp assays of patient samples.
CTLp assays were carried out on the peripheral blood samples received before 
transplantation and on two occasions after transplantation from each patient. The 
patient's mononuclear cells were used as the responder cell population in all of the 
assays. For each sample CTLp frequencies were determined against both the cardiac 
donor and a 3rd party which shared no HLA-A,-B or -DR antigens with the cardiac 
donor. Spleen mononuclear cells from the cardiac donor and the 3rd party were used as 
stimulator cells in each case. An additional unrelated cell was used as a control in each 
assay as described.
15. Statistical analysis of results.
CTLp assays not consistent with single hit kinetics (chi^ values with p<0.05) were 
excluded from the statistical analysis. For tests which compared results in the different 
sample time groups, patients were included only if all three donor-reactive or 3“‘ party- 
reactive CTLp frequencies were available.
Pre-transplant donor- and 3'^ '^  party-reactive CTLp frequencies grouped by the number of 
HLA mismatches between recipient and donor were compared using the Mann-Whitney 
T statistic. CTLp frequencies were compared between patients with the following HLA 
mismatches: 0,1 and 2 HLA-A and -B mismatches compared with 3 and 4 HLA-A and 
-B mismatches; 0,1 and 2 HLA-DR and -DQ mismatches compared with 3 and 4
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HLA-DR and -DQ mismatches; 0 to 4 HLA-A, -B, -DR and -DQ mismatches compared 
with 5 to 8 HLA-A, -B, -DR and -DQ mismatches. HLA mismatches were defined as 
the number of donor HLA antigens not present in the recipient.
The relation between pre-transplant donor- and party-reactive CTLp frequencies and 
EMB-diagnosed rejection (number of EMB graded > 2 by 90 days and by 1 year after 
transplantation, summed grades of EMB graded > 2 by 90 days and by 1 year after 
transplantation, number of days to first EMB graded > 2) was investigated using the 
Spearman rank correlation coefficient. Summed EMB grades were used to reflect the 
severity and persistence of rejection.
CTLp frequencies in the different sample time groups (Tl, T2 and T3) were compared 
using the sign test with paired frequencies.
Donor-reactive CTLp frequencies from samples taken at the time of grade 0 or 1 EMB 
were compared with donor-reactive CTLp frequencies from samples taken at the time of 
grade 2 or 3 EMB using the Mann-Whitney T statistic (there were no grade 4 EMB at 
any of the sampling times).
The relation between post-transplant CTLp frequencies and rejection was analysed by 
the Spearman rank correlation test. Spearman rank correlation co-efficients (n ) were 
calculated for the T2 sample CTLp frequencies and the number and summed grades of 
EMB graded > 2 in the period up to the sampling time; for the T3 sample CTLp 
frequencies and the number and summed grades of EMB graded > 2 in the period
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between the T2 and T3 samples; and for the T3 sample CTLp frequencies and the 
number and summed grades of EMB graded > 2 in the period from transplantation to the 
T3 samples.
The relation between T3 CTLp frequencies and total doses of CsA and azathioprine 
received, and T3 CTLp frequencies and the number of additional courses of steroids 
received for acute rejection were analysed by the Spearman rank correlation test.
Donor- and 3'^ party-reactive CTLp frequencies at each of the two post-transplant 
sample time groups (T2 and T3) were compared between patients who received 
induction therapy with ATG and patients who received standard triple 
immunosuppression using the Mann-Whitney T statistic.
Test statistics were calculated using the methods and tables described by Altman (387).
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RESULTS
1. Assessment of the Matrix 96 Direct Beta Counter.
1.1. Determination of counting time for the Matrix 96 Direct Beta Counter.
A 19 min count using the Matrix 96 gave results which most closely matched the gamma 
counter cpm in both the range of counts observed (table 2), and the mean of 16 replicate 
wells at each dilution (figures 1 and 2).
At low values Matrix 96 counts were less than gamma cpm, because of the lower 
background counts of the Matrix 96. Regression lines extrapolated to zero labelled cells 
gave a background of about 30 counts for the 19 min Matrix 96 count compared to 
about 68 cpm for the gamma counter. For 19 min counts the mean calculated cpm of 
the Matrix 96 were about 5 - 6 % of gamma counter cpm over most of the counting 
range, falling to 4.8 % at 200 cells per well and 3.9 % at 100 cells per well.
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Dilution range
Gamma counter Matrix 96 counts
cpm 17 min 18 min 19 min
10000 to 1000 
cells/well
1000 to 100 
cells/well
364 to 2495 
100 to 601
327 to 2355 
NT
327 to 2520 
46 to 602
363 to 2634 
68 to 683
Table 2. Ranges of counts from samples counted in the gamma counter and the Matrix 
96. Ranges shown are from 96 samples (16 replicates at each of 6 dilutions), counted 
once for each time interval. NT = not tested.
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1.2. Comparison of the Matrix 96 with a gamma counter.
1.2.1. Agreement of the counters.
A plot of a 19 min Matrix 96 count against gamma counter cpm for the same samples is 
shown in figure 3. The differences between the counts by each method were plotted 
against their means (figure 4). The differences between the counters changed from 
positive at low values to negative at high values, that is, gamma cpm were higher than 
Matrix 96 counts at low values and lower than Matrix 96 counts at high values.
The limits of agreement (with 95 % Cl for upper and lower limits) of the Matrix 96 and 
gamma counter were -69.2 (-82.3 to -56.1) to 79.6 (66.5 to 92.7).
1.2.2. Repeatability of the counters.
Plots of the differences between two sets of counts against their means for each method 
are shown in figures 5 and 6. The differences between repeated Matrix 96 counts 
increased with increasing ^^Cr-release, but were less than the differences between 
repeated gamma counter counts at low values. The gamma counter showed similar 
differences over the whole range of values. The co-efficients of repeatability, as defined 
in the methods, were 50.0, 48.2 and 54.3 between the three sets of gamma counter cpm 
and 57.6, 52.8 and 52.3 between the three Matrix 96 counts. The co-efficient of 
repeatability between the gamma counter and the Matrix 96 using two repeated sets of 
measurements for each counter was 74.4.
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The mean differences for repeated measurements using the gamma counter were not 
significantly different from zero. For the Matrix 96, the mean difference for repeated 
measurements was less than zero for two of the three comparisons (counts 1 and 2, 
mean = -10.3 (95 % confidence inteiwal = -16.1 to -4.5); counts 1 and 3, mean = -6.2 
(95 % confidence interval = -11.6 to -0.8). 94.8 % of differences were within two SD of 
the mean for the gamma counter and 93.75 % of differences were within 2 SD of the 
mean for the Matrix 96. The Matrix 96 differences were related to the mean, however 
(figure 6), and when the data were logio transformed 95.8 % of differences were within 
two standard deviations of the mean.
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2. Assessment of natural kilier-like activity in the CTLp assay.
2.1. K562-directed cytotoxicity in CTLp assays.
The HLA types of the responder and stimulator cells used in the assays of K562-directed 
cytotoxicity are shown in table 3. K562~directed cytotoxicity was present in CTLp 
assay cultures in an assay between an HLA-identical sibling pair and in three assays 
between unrelated individuals with varying numbers of HLA mismatches. The maximum 
specific lysis was about 70 % in three of the assays (figures 7 to 10). In assay 2, 
different dilutions of responder cells were used due to a shortage of cells.
The CTLp frequency for assay 1 was 3 cells per million peripheral blood MNC
(95 % confidence inteiwal = 2 to 7 cells per million, chi  ^= 3.15, p = 0.53) and for assay 2 
was 1190 cells per million peripheral blood MNC (95 % confidence interval = 829 to 
1709 cells per million, chf = 0.19, p ^  1.0). Specific lysis ofK562 cells was similar in 
each unrelated combination and appeared not to be influenced by the nature of the HLA 
mismatch.
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K562
Assay Cell Cell type
HLA locus
A B Cw DR
1 R PBMNC 3 29 39 44 . NT
S PBMNC 3 29 39 44 - - NT
2 R PBMNC 2 3 7 - 7 15
S SMNC 1 2 8 37 6 - 3 7
3 R PBMNC 2 3 7 15 3 - 15 13
S SMNC 2 28 35 60 3 4 4
4 R PBMNC 2 3 7 35 4 - NT
S SMNC 2 25 35 57 4 6 7 8
Table 3. HLA phenotypes of responder and stimulator cells used for the assessment of 
K562“directed cytotoxicity in CTLp assays. R = responder, S = stimulator, PBMNC = 
peripheral blood mononuclear cells, SMNC = spleen mononuclear cells, NT = not tested.
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2.2. Determination of target cell ratios for cold target competition experiments.
The results of the experiment to determine an appropriate cold : hot target cell ratio for 
competition experiments are shown in figure 11. As expected, unlabelled stimulator-type 
PHA blasts inhibited the release of ^ ^Cr from the same stimulator-type targets and 
unlabelled K562 inhibited release of ^ ^Cr from K562 targets. Unlabelled stimulator-type 
PHA blasts did not inhibit release of ^ ^Cr from K562, but a trend towards increased lysis 
of K562 was seen with the addition of increasing numbers of unlabelled PHA blast cells. 
However, the increase was small at the 20 : Î ratio (2.8 %), and this ratio was chosen for 
subsequent competition experiments because it gave good homologous inhibition and 
was less demanding in numbers of cells.
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2.3. Cold target competition by stimulator-type PHA blasts of killing of K562 
targets.
The HLA types of the responder and stimulator cells used in competition assays 1 to 5 
are shown in table 4. Specific lysis in the presence and absence of unlabelled competitors 
in each of the assays is shown in figures 12 to 16.
^^Cr release was augmented by the unlabelled stimulator-type PHA blast cells in the 
absence of responder cells and at low responder cell numbers in four of the assays. At 
higher responder cell numbers the ^^Cr release was similar in the presence and absence of 
cold competitors, with the exception of assay two, in which specific lysis of K562 targets 
was higher in the presence than in the absence of unlabelled competitor cells at each 
responder cell dilution.
The CTLp frequency of responder cells reactive with the stimulator cell type in each of 
the assays is shown in table 5. In assays one and two the numbers of positive wells at the 
4 X 10"^  responder cell concentration were inconsistent with single-hit kinetics. This 
could have resulted from overgrowth of the cultures due to the high numbers of 
proliferating lymphocytes at these cell concentrations. It was considered valid to 
calculate adjusted CTLp frequencies with these values omitted, using values from the 
straight-line part of the limiting dilution curve.
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Competition
Assay Cell Cell type
HLA locus
A B Cw DR
1 R PBMNC 2 3 7 15 3 15 13
S SMNC 2 28 35 60 3 4 4
2 R PBMNC 2 3 7 - 7 - 103 15
S SMNC 2 28 35 60 3 4 4
3 R PBMNC 1 3 8 60 3 7 17 13
S SMNC 30 31 13 18 5 6 7 14
4 R PBMNC 1 26 22 37 6 - 10 14
S SMNC 30 31 13 18 5 6 7 14
5 R PBMNC 2 3 7 » 7 - 8 13
S SMNC 1 2 8 44 - - 17 4
Table 4. HLA phenotypes of responder and stimulator cells used in assays of cold target 
competition by stimulator-type PHA blasts of K562 killing. R = responder,
S = stimulator, PBMNC = peripheral blood mononuclear cells, SMNC = spleen 
mononuclear cells. PBMNC were from normal individuals and SMNC were from 
cadaver donors.
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Competition Assay CTLp 95% Cl Chi^ P
1 36“ 25 - 53 7.15 0.13
2 147“ 111 - 193 2.70 0.61
3 1050 741 - 1488 0.97 0.97
4 71 54 - 94 1.44 0.92
5 177 135 - 232 8.08 0.15
Table 5. Stimulator cell-specific CTLp frequencies in assays used to investigate cold 
target competition by stimulator-type PHA blasts of K562 killing. CTLp = frequency per 
million peripheral blood MNC. a = adjusted CTLp frequency.
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2.4. Cold target competition by K562 cells of killing of stimulator-type targets.
The HLA types of the responders and stimulators used in competition assays 6 to 10 are 
shown in table 6. The CTLp frequencies of responder cells reactive with the stimulator 
cell type in the presence and absence of unlabelled K562 competitors are shown in 
table 7.
While there appears to be a trend towards inhibition, with the exception of assay 9 the 
CTLp frequencies obtained in the presence and absence of unlabelled competitors had 
overlapping confidence intervals and were thus not significantly different from each 
other.
In assay 10, in the presence of unlabelled K562, the 3 x 10"^  and 4 x 10"^  responder cell 
concentrations contained fewer positive wells than higher dilutions and were inconsistent 
with single-hit kinetics. An adjusted CTLp frequency was calculated with these values 
omitted, using values from the straight-line part of the limiting dilution curve.
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Competition
Assay Cell Cell type
HLA locus
A B Cw DR
6 R PBMNC 1 25 18 15 8
S SMNC 2 29 44 52 " 4
7 R PBMNC 3 11 7 44 - 2 7
S SMNC 2 29 44 52 - 4
8 R PBMNC 1 26 18 — — 11 13
S SMNC 2 3 51 18 2 11
9 R PBMNC 2 26 35 60 3 4 1 103
S SMNC 2 3 14 44 5 4 13
10 R PBMNC 1 34 8 13 — “ 2 7
S SMNC 1 2 7 8 7 103 17
Table 6. HLA phenotypes of responder and stimulator cells used in assays of cold target 
competition by K562 cells of killing of stimulator-type targets. R -  responder,
S = stimulator, PBMNC = peripheral blood mononuclear cells, SMNC = spleen 
mononuclear cells. Responders in assays 6 and 8 were normal individuals and responders 
in assays 7, 9 and 10 were cardiac transplant recipients tested against their donors.
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Competition
Assay Competitor CTLp 95% Cl Chi^ P
6 No competitor 409 311 - 538 16.19 0.02
K562 289 221 - 379 14.27 0.05
7 No competitor 158 122 - 204 2.69 0.91
K562 103 80- 131 19.64 0.006
8 No competitor 485 368 - 640 6.25 0.51
K562 393 299 - 517 10.01 0.19
9 No competitor 121 96 - 154 10.37 0.17
K362 71 56-91 14.92 0.04
10 No competitor 87 69-111 11.50 0.12
K562 80“ 59 - 107 7.12 0.21
Table 7. Stimulator cell-specific CTLp frequencies in the presence and absence of 
unlabelled K562 competitors. CTLp = frequency per million peripheral blood MNC. 
a = adjusted CTLp frequency.
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3. Reproducibility of the CTLp assay.
The CTLp frequencies obtained from the same responder-stimulator pair assayed on 
different dates had overlapping confidence intervals, and were thus not significantly 
different from each other (table 8). Intra-assay reproducibility was demonstrated in assay 
three.
Repeated assay CTLp 95% Cl Chf P
1 81 64 - 102 10.9 0.14
2 111 87- 141 10.7 0.15
3* 97 76 - 123 7.4 0.39
3* 83 66- 104 11.8 0.11
Table 8. CTLp frequencies for a responder-stimulator pair tested on different occasions. 
CTLp = frequency per million peripheral blood MNC. * Tested in duplicate from the 
same starting cell populations.
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4. Analysis of CTLp frequency in cardiac transplant recipients.
4.1. HLA typing of patients, donors and 3“* party cells.
HLA typing results are shown in table 9. All patients had a negative crossmatch with 
donor T and B lymphocytes, except GS and TF who had negative T cell, but positive 
B cell crossmatches.
4.2. Donor- and 3‘ party-reactive CTLp frequencies.
The donor-reactive and 3**^ party-reactive CTLp fiequencies for all patients before 
transplantation and at two time points after transplantation are shown in table 10. In 
four assays, the numbers of positive wells at one or two responder cell dilutions were 
inconsistent with single-hit kinetics. After examination of the results it was considered 
valid to omit these data points from the analysis. Adjusted CTLp frequencies were 
calculated with these values omitted, using values from the straight-line part of the 
limiting dilution curve.
Limiting dilution curves representative of different patterns of change after 
transplantation are shown in figures 17 and 18. Figure 17 shows assays of donor- 
reactive CTLp frequency for patient IM, in which CTLp frequency decreased at both 
sampling times after transplantation. In the assays for patient GS represented in figure 
18, the donor-reactive CTLp frequency decreased in the T2 sample, then increased in the 
T3 sample.
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Identification
HLA locus
A B Bw Cw DR DQ
IM 3 11 7 44 4 6 15 7 51 53 2 6
Donor 2 29 44 52 4 - - 4 - 53 - 7 8
3"" party 1 26 8 - 6 7 - 17 - 52 - 2
PK 1 31 8 60 6 3 7 15 4 51 53 6 8
Donor 3 32 7 18 - 6 - - 4 13 52 53 6 7
3"'^  party 1 2 8 37 4 6 6 7 17 7 52 53 2 -
SS 2 3 62 18 6 3 4 53 7 8
Donor 2 11 35 49 4 6 NT 103 4 53 - 5 8
3^"^  party 30 31 13 18 4 6 5 6 7 14 52 53 2 5
GM 2 23 44 62 4 6 3 4 17 4 52 53 2 8
Donor 24 28 7 44 4 6 - - 15 7 51 53 2 6
3'"^  party 2 - 62 27 4 6 3 - 4 “ 53 - 8
RF 3 32 22 35 6 3 4 1 4 53 _ 5 7
Donor 1 - 7 60 - 6 3 7 4 13 52 53 6 8
3“* party 24 11 62 56 - 6 1 3 1 11 52 - 5 7
JH 1 3 7 6 17 11 52 2 7
Donor 1 - 8 44 4 6 - - 17 7 52 53 2
3'"^  party 3 31 51 60 4 6 3 4 11 52 53 7 8
GS 2 26 35 60 6 3 4 1 103 5
Donor 2 3 44 14 4 6 5 - 4 13 52 53 6 7
3*'® party 1 11 57 50 4 6 6 - 7 - 53 - 2 9
WM 1 34 8 13 4 6 15 7 51 53 2 6
Donor 1 2 7 8 6 7 103 17 52 - 2 5
3''® party 3 31 51 60 4 6 3 - 4 11 52 53 7 8
JC 2 3 35 44 4 6 4 5 1 13 52 5 6
Donor 2 3 51 18 4 6 2 - 11 - 52 - 7 **
3"® party 1 26 45 57 4 6 6 - 4 7 53 - 7 9
TF 2 3 35 51 4 6 4 4 11 52 53 7 8
Donor 2 - 44 - - 5 - 4 53 - 7 -
3'"® party 30 31 13 18 4 6 5 6 7 14 52 53 2 5
Table 9. HLA typing of patients 1 to 10, their cardiac donors and S"** party cells used in 
the CTLp assays. NT = not tested. (Contd. over).
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Identification
HLA locus
A B Bw Cw DR DQ
GF 1 2 8 44 4 6 5 - 15 4 51 53 6 7
Donor 1 2 8 62 - 6 3 7 17 4 52 53 2 8
3''® party 25 32 18 47 4 6 2 - 11 15 51 52 6 7
AM 2 11 7 27 4 6 2 - 1 4 53 5 7
Donor 1 - 8 39 - 6 "  - 4 14 52 53 5 8
3*‘® party 3 34 7 - - 6 7 - 15 - 51 - 6 -
TD 2 11 7 50 6 6 7 7 14 52 53 2 5
Donor 1 31 8 - 6 7 - 17 - 52 - 2 -
3'“® party 2 11 5 44 4 - 5 - 15 4 51 53 6 8
WB 1 7 8 6 NT 15 17 51 52 2 6
Donor 2 11 8 35 - 6 NT 103 11 52 - 5 7
3"® party 3 28 18 62 - 6 3 - 12 14 52 “ 5 7
ID 2 3 8 49 4 6 7 - 17 4 52 53 2 8
Donor 2 11 35 60 - 6 3 4 4 - 53 - 7 8
3"® party 26 32 17 62 4 6 3 6 7 14 52 53 7 9
Table 9 (contd.). HLA typing of patients 11 to 15, their cardiac donors and 3“^^  party 
cells used in the CTLp assays. NT = not tested.
112
Patient Specificity Day CTLp 95 % Cl Chi^ P
IM Donor 0 1479 1106-1976 0.80 0.85
82 728 537-989 3.91 0.79
356 304 237-389 8.75 0.27
3'"® Party 0 216 139-335 2.64 0.45
82 410 316-532 2.06 0.96
356 185 146-234 7.59 0.37
PK Donor 0 590 443-786 3.21 0.86
104 136 108-171 4.20 0.76
272 429“ 330-559 8.88 0.18
3'“® Party 0 7518 75-1x10* 0.00 1.0
104 475 360-627 0.96 1.0
272 1131 818-1562 0.35 1.0
SS Donor 0 1122 830-1517 3.81 0.70
91 623 476-816 6.61 0.47
259 536 413-696 4.41 0.73
3"' Party 0 758 572-1004 4.47 0.72
91 594 455-775 6.04 0.54
259 766 578-1014 5.84 0.56
GM Donor 0 351 264-467 2.23 0.95
80 41 31-54 7.85 0.35
290 14 10-19 15.68 0.03
3“* Party 0 399 299-533 11.75 0.11
80 320 251-407 11.62 0.11
290 135 107-170 11.76 0.11
RF Donor 0 293 231-372 18.41 0.01
200 36 28-47 7.38 0.39
257 150 116-193 16.14 0.02
3'"® Party 0 375 293-479 6.21 0.52
200 27 20-36 12.64 0.08
257 216 166-282 14.57 0.02
Table 10. Frequencies of donor-reactive and 3"^ ®^ party-reactive CTLp for patients 1 to 5. 
CTLp = frequency per million peripheral blood MNC. 95 % Cl = 95 % confidence 
intei*val for the frequency estimate, a = adjusted CTLp frequency. (Contd. over).
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Patient Specificity Day CTLp 95 % Cl Chi^ ....E.._
JH Donor 0 117 91-151 13.08 0.04
163 254 194-332 11.12 0.05
289 19 11-31 5.62 0.35
3 '' Party 0 699 530-920 5.94 0.55
163 628 473-833 4.50 0.72
289 216 166-281 4.50 0.72
GS Donor 0 109“ 85-141 11.46 0.08
112 28 21-37 7.16 0.41
455 110 86-140 12.10 0.10
3"® Party 0 334 262-426 9.72 0.21
112 64 50-82 3.81 0.80
455 136 106-174 6.27 0.51
WM Donor 0 362“ 277-471 6.23 0.18
85 79 62-100 8.64 0.28
295 82 64-105 11.22 0.13
3"® Party 0 582“ 446-759 7.43 0.19
85 220 168-287 8.31 0.30
295 2304 1545-3436 0.50 1.0
JC Donor 0 342 260-449 3.07 0.88
112 53 42-68 10.55 0.16
373 28 21-37 16.32 0.02
3"' Party 0 174 135-226 19.52 0.007
112 72 57-92 12.30 0.09
373 104 82-133 7.90 0.34
TF Donor 0 102 79-132 4.75 0.58
124 AF
306 255 195-333 12.13 0.06
3"® party 0 198 153-258 12.18 0.06
124 AF
306 256 196-335 10.64 0.16
Table 10 (contd.). Frequencies of donor-reactive and 3’^'® party-reactive CTLp for 
patients 6 to 10. CTLp = frequency per million peripheral blood MNC. 95 % Cl = 95 % 
confidence intei*val for the frequency estimate, a = adjusted CTLp frequency.
AF = assay failure. (Contd. over).
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Patient Specificity Day CTLp 95 % Cl Chi" P
GF Donor 0 74 58-93 10.47 0.16
121 26 19-37 21.41 0.002
303 130 99-171 10.64 0.06
3"' Party 0 168 130-217 10.59 0.16
121 259 198-339 24.30 0.001
303 685 515-912 14.70 0.01
AM Donor 0 256 196-335 14.43 0.04
105 94 72-123 20.90 0.002
303 125 97-161 7.83 0.35
3’’'® Party 0 512 388-677 3.93 0.79
105 121 93-158 17.40 0.008
303 139 106-182 2.61 0.76
TD Donor 0 295 225-386 7.60 0.37
79 146 112-190 6.60 0.36
273 335 255-439 5.20 0.64
3’"'® party 0 281 214-367 3.93 0.79
79 98 75-129 7.23 0.30
273 156 121-202 16.15 0.02
WB Donor 0 1149 848-1557 11.97 0.10
85 155 120-201 6.69 0.46
3'"® party
301 505 382-667 5.84 0.56
0 410 311-539 10.91 0.09
85 150 115-195 13.10 0.04
301 188 145-244 14.41 0.04
JD Donor 0 404 307-531 14.50 0.04
102 165 128-213 5.67 0.58
3'"® party
354 605 456-802 5.78 0.57
0 610 460-809 9.92 0.19
102 351 267-461 15.42 0.03
354 746 560-995 3.51 0.83
Table 10 (contd.). Frequencies of donor-reactive and 3"® party-reactive CTLp for 
patients 11 to 15. CTLp = frequency per million peripheral blood MNC.
95 % Cl = 95 % confidence interval for the frequency estimate.
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Figure 17. Limiting dilution curves of donor-reactive 
CTLp assays for patient IM pre-transplant (T l) and at three 
months (T2) and one year (T3) post transplant. Log to base e 
of the fraction of negative cultures (InFo) was plotted at each 
responder cell concentration. Responder concentrations with 
all cultures positive were omitted. A straight line was fitted to 
the points by regression analysis.
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Figure 18. Limiting dilution curves of donor-reactive CTLp 
assays for patient GS pre-transplant (T l) and at 4 months (T2) 
and 15 months (T3) post transplant, Log to base e of the 
fraction of negative cultures (InFo) was plotted at each 
responder cell concentration. Responder concentrations with 
all cultures positive were omitted. A straight line was fitted to 
the points by regression analysis.
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4.3. Acute rejection and immunosuppression.
The number of EMB graded > 2 in the first 90 days and in the first year after 
transplantation ranged from 0 to 5 (median 2), and 1 to 10 (median 3), respectively.
The time from transplantation to the first EMB graded > 2 ranged from 15 to 124 days 
(median 29 days). Details o f EMB results are given in table 11.
Total doses of CsA and azathioprine received by patients ranged from 64,200 to 
141,575 mg (median 111,025 mg), and 18,750 to 67,525 mg (median 45,520 mg), 
respectively. The number of additional courses of steroids given to treat acute rejection 
ranged from 0 to 6 (median 2). Details of immunosuppression are given in table 12.
4.4. Comparison of pre-transplant CTLp frequencies in patients grouped by the 
number of HLA mismatches with their donor.
Pre-transplant donor- and 3"* party-reactive CTLp frequencies grouped by the number of 
HLA mismatches between recipient and donor were compared using the Mann-Whitney 
T statistic. Pre-transplant donor-reactive CTLp frequencies were lower in the HLA-A, 
-B, -DR and -DQ 0 to 4 mismatch group than the HLA-A, -B, -DR and -DQ 5 to 8 
mismatch group (figure 19, p < 0.05, n = 10). No differences were seen in donor- 
reactive CTLp frequencies grouped by HLA class I or class II mismatches independently, 
or in 3'^ party-reactive CTLp frequencies in any of the mismatch groups.
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1
Patient
T l to T2" T2 to T3 Tl + 90 days T l + 1 year Days to 
first'*14o7 Sum" No. Sum No. Sum No. Sum
IM 3 8 2 5 3 8 5 13 34
PK 1 2 0 0 0 0 1 2 104
SS 3 6 1 2 3 6 4 8 16
GM 1 3 0 0 1 3 1 3 15
RF 2 6 0 0 0 0 3 9 124
JH 2 4 4 9 1 2 7 15 30
GS 5 15 0 0 5 15 5 15 27
WM 3 9 3 8 3 9 10 25 29
JC 2 5 1 3 2 5 3 8 21
TF 4 11 2 5 3 8 6 16 22
GF 1 3 2 5 : 3 4 12 46
AM 2 5 1 2 2 5 3 7 16
TD 1 2 1 3 2 5 2 5 48
WB 2 4 0 0 2 4 2 4 22
JD 2 6 1 2 1 3 3 8 32
Table 11. Summaiy of EMB results for the 15 cardiac transplant recipients, a = time 
interval during which EMB took place (Tl = pre-transplant, T2 = 79 to 200 days post­
transplant, T3 = 257 to 455 days post-transplant), b = number of EMB graded > 2, 
c = summed grades of EMB graded > 2 (eg. one grade 2 EMB and two grade 3 EMD 
gives sum of 8), d = number of days from transplantation to first EMB graded > 2.
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Patient Cyclosporin A (mg)“ Azathioprine (mg) ^ Courses of steroids
IM 82675 47925 3
PK 88750 25725 1
SS 125325 46900 3
GM 64200 32775 1
RF 92400 18750 2
m 109950 27775 4
GS 122700 47800 6
WM 111025 61250 5
JC 140625 59375 3
TF 141575 51125 5
GF 102475 42250 2
AM 135950 67525 2
TD 90675 34075 2
WB 120750 36750 0
JD 118220 45520 2
Table 12. Suirunaiy of immunosuppression received by the 15 cardiac transplant 
patients, a and b = total dose of CsA and azathioprine, respectively, given to each 
patient in the period from transplantation to the T3 sample, c = total number of 
additional courses of steroids given for acute rejection in the period from transplantation 
to the T3 sample. Full details of immunosuppression protocols are given in the methods.
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Figure 19. Pre-transplant donor-reactive CTLp frequencies (CTLp 
per million peripheral blood MNC (PBMNC)) grouped by number of 
HLA-A, -B, -DR and -DQ mismatches (MM) between recipient and 
donor. Frequencies were lower in the better matched group (p < 0.05). 
The medians are shown by horizontal lines.
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4.5. Relation between pre-transplant CTLp frequency and acute rejection.
The relation between pre-transplant donor- and 3“* party-reactive CTLp frequencies and 
EMB-diagnosed rejection (number of EMB graded > 2 by 90 days and by 1 year after 
transplantation, summed grades of EMB graded > 2 by 90 days and by 1 year after 
transplantation, number of days to first EMB graded > 2) was investigated using the 
Spearman rank correlation coefficient. No correlation was found with p < 0.05.
4.6. CTLp frequencies in cardiac transplant recipients.
Pre-transplant donor- and 3'^ '* party-reactive CTLp frequencies were high before 
transplantation, ranging from 74 to 7518 CTLp per million peripheral blood MNC 
(median 375).
In assays with single-hit kinetics, by 3 to 7 months after transplantation donor-reactive 
CTLp frequencies were lower than pre-transplant frequencies in nine patients, but by 9 to 
15 months this number had fallen to four (table 10). 3“* party-reactive CTLp frequencies 
after transplantation were lower than pre-transplant frequencies in four patients at both 
post-transplant time inteiwals, indicating that changes in CTLp frequency were not 
always donor-specific. Two patients had higher donor-reactive CTLp frequencies and 
one patient had a higher 3”'* party-reactive CTLp frequency by 9 to 15 months after 
transplantation compared to pre-transplant frequencies. Changes in 3"'* party-reactive 
CTLp frequencies were seen less frequently than changes in donor-reactive CTLp 
frequencies (table 10).
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The largest decrease in donor-reactive CTLp frequency by 9 to 15 months after 
transplantation was by 4- to 5-fold in two patients, IM and WM, with T3 frequencies of 
304 and 82 per million peripheral blood MNC, respectively. The frequency in one other 
patient (JH) was 19 CTLp per million peripheral blood MNC 9 months after 
transplantation, but the pre-transplant frequency estimate did not conform to single-hit 
kinetics so a comparison could not be made. Donor-reactive CTLp frequency decreased 
by 8-fold (to 41 cells per million) in patient GM, and 6-fold (to 53 cells per million) in 
patient JC by 2 to 4 months after transplantation. Donor-reactive cytotoxicity decreased 
further by 9 to 12 months in these patients, but these assays had non-single hit kinetics.
4.7. CTLp frequencies at different sampling times in the group of patients.
CTLp frequencies in the different sample time groups (Tl, T2 and T3) were compared 
using the sign test with paired frequencies. Only the donor-reactive pre-transplant (T l) 
and 3 to 7 month (T2) CTLp frequency groups were different (figure 20, p = 0.02, 
n = 7). No significant differences were seen in 3'** party-reactive CTLp frequencies 
between any of the thi ee time groups, or when donor- and 3'^ '* party-reactive CTLp 
frequencies were compared at each of the time intervals.
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Figure 20. Donor-reactive CTLp frequencies (CTLp per million 
peripheral blood MNC (PBMNC)) pre-transplant (Tl), and at 3-7 
months (T2) and 9-15 months (T3) after transplantation.
*** Pre-transplant and T2 frequencies were different (p = 0.02). There 
were no other significant differences between groups. The medians are 
shown by horizontal lines.
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4.8. Serial changes in CTLp frequency in individual patients.
Donor-reactive CTLp frequencies with single-hit kinetics were available at all three 
sampling intervals for seven patients. Donor-reactive CTLp frequencies decreased at the 
first post-transplant sample in all seven patients, but thereafter the patterns of change 
differed, with one patient showing a further decrease, two patients no ftirther change and 
four patients showing an increase in CTLp frequency (figure 21). A concomitant 
decrease in 3“' party reactive CTLp frequency was seen in three samples (WM, TD and 
GS, T2 samples).
4.9. Comparison of post-transplant CTLp frequencies grouped by acute rejection 
grade.
Donor-reactive CTLp frequencies from samples taken at the time of grade 0 or 1 EMB 
were compared with donor-reactive CTLp frequencies from samples taken at the time of 
grade 2 or 3 EMB using the Mann-Whitney T statistic (there were no grade 4 EMB at 
any of the sampling points). No difference between the two groups was seen when the 
T2 and T3 samples were analysed together (p > 0.1, n = 22). Similarly, no difference 
was seen between the two groups in the T2 samples (p>0.1,  n = l l ) .  In the T3 samples 
donor-reactive CTLp frequencies were lower in samples taken at the time of grade 2 or 3 
EMB than grade 0 or 1 EMB (figure 22, p < 0.05, n = 11).
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Figure 21. Serial changes in donor-reactive CTLp frequency (CTLp 
per million peripheral blood MNC (PBMNC)) for seven patients.
Tl = pre-transplant, T2 = 3-7 months post- transplant, T3 = 9-15 
months post-transplant.
126
10000
1000
u
s
§
p.
è
100  -
10  -
° o °
Grades 0 and 1 Grades 2 and 3
Figure 22, T3 (9-15 months post-transplant) donor-reactive CTLp 
frequencies (CTLp per million peripheral blood MNC (PBMNC)) from 
samples taken at the time of EMB graded 0 and 1 and EMB graded 2 
and 3. Frequencies were lower at the time of grade 2 and 3 EMB 
(p <0.05). The medians are shown by horizontal lines.
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4.10. Relation between post-transplant donor-reactive CTLp freqnencies and 
rejection in preceding periods.
Spearman rank correlation co-efficients (i\ ) were calculated for the T2 sample CTLp 
frequencies and the number and summed grades of EMB graded > 2 in the period up to 
the sampling time. Similar calculations were made for the T3 sample CTLp frequencies 
and the number and summed grades of EMB graded > 2 in the period between the T2 
and T3 samples, and the T3 sample CTLp frequencies and the number and summed 
grades of EMB graded > 2 in the period from transplantation to the T3 samples. A 
significant negative correlation was found for the T3 sample donor-reactive CTLp 
frequencies and number of EMB graded > 2 in the period from transplantation to the T3 
samples (r^  = - 0.71, 0.05 > p > 0.02, n = 9, figure 23).
Donor-reactive CTLp frequencies in the T3 samples did not correlate with the total dose 
of CsA or azathioprine received in the period from transplantation to the T3 sample. 
There was a negative correlation of donor-reactive CTLp frequencies with the number of 
additional courses of steroids in the period from transplantation to the T3 samples, but 
this did not reach significance (I's = -0.56, 0.1 > p > 0.05, n = 12, figure 24).
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Figure 23. Donor-reactive CTLp frequencies (CTLp per million 
peripheral blood MNC (PBMNC)) at T3 (9-15 months post-transplant) 
plotted against number of EMB graded 2 and above from transplantation 
to T3.
0.05 >
A significant negative rank conelation was found (rs = - 0.71,
p > 0.02).
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Figure 24, Donor-reactive CTLp frequencies (CTLp per million 
peripheral blood MNC (PBMNC)) at T3 (9-15 months post-transplant) 
plotted against number o f courses of steroids from transplantation toT3. 
Ranlc correlation was not significant (rs = -0.56, 0.1 > p > 0.05).
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3'"^  party-reactive CTLp frequencies with single-hit kinetics were available for the T2 and 
T3 samples for six of these patients, but no significant correlation was found. The 
negative correlation between the T3 sample donor-reactive CTLp frequencies and 
number of EMB graded > 2 in the period from transplantation to the T3 samples was 
higher for these six patients than the initial nine (r* = -0.87, 0.02 > p > 0.01), however 
the correlation with summed EMB grades did not reach significance (r^  = -0.73,
0.1 >p>0 .05) .
4.11. Influence of induction immunosuppression with ATG on CTLp frequency.
Donor- and party-reactive CTLp frequencies at each of the two post-transplant time 
groups were compared between patients who received induction therapy with ATG and 
patients who received standard triple immunosuppression. The Mann-Whitney T 
statistic was used for comparisons. No differences between ATG-treated patients and 
patients given standard triple immunosuppression were seen in donor-reactive (n = 9) or 
3"^  party-reactive (n = 8) CTLp frequencies.
131
DISCUSSION
1. Assessm ent of the M atrix 96 Direct Beta Counter.
1.1. Determination of counting time for the Matrix 96 Direct Beta Counter.
A 19 min count using the Matrix 96 gave results which most closely matched the gamma 
counter cpm. Counts in the lower part of the range tested were given greater 
consideration than higher counts because the threshold value for defining positive wells 
in the CTLp assay is usually less than 500 counts. The divergence seen at liigher counts 
was considered acceptable, as values in this region would be positive in a CTLp assay.
For the 19 min count the calculated mean cpm of the Matrix 96 were about 5 - 6 % of 
gamma cpm over most of the counting range, falling to 4.8 % at 200 cells and 3.9 % at 
100 cells. The latter two values were lower because the Matrix 96 counts fell below the 
gamma counts at these cell numbers. Converting these values for equivalent sample 
volumes gives a Matrix 96 counting efficiency of 10- 12 % of the gamma counter over 
most of the range. This compares to a value of 17 % reported previously (12). This 
difference could be explained by the different harvesting procedures used for the gamma 
counters. The value of 17 % efficiency was obtained by counting 150 pi supernatant, 
compared to 100 pi in the present study. A different model of gamma counter was used 
in the previous work and this may also have had a different counting efficiency from the 
model used in this study.
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1.2. Comparison of the Matrix 96 with a gamma counter.
1.2.1. Agreement of the counters.
The limits of agreement of the Matrix 96 and gamma counter were -69.2 to 79.6.
Matrix 96 counts may thus be 69.2 less or 79.6 more than cpm obtained by the gamma 
counter. While these differences appear large, with increasing counts the between 
counter bias changes from positive to negative with respect to the gamma counter (figure 
4). The analysis may tend to overestimate the limits of agreement under such 
circumstances due to the complexity of the relationship (14).
1.2,2. Repeatability of the counters.
Differences between the counters were anticipated in view of the variation in repeated 
counts by each counter. Both counters had good repeatability. After log transformation, 
more than 95 % of differences between repeated counts using the Matrix 96 were within 
2 SD of the mean. The co-efficient of repeatability for the Matrix 96 was similar to that 
for the gamma counter. Differences between repeated counts were less for the Matrix 96 
than for the gamma counter at lower ^^Cr-release values (figures 5 and 6) which are 
critical for defining positive wells in the CTLp assay. The co-efficients of repeatability 
for repeated counts by either counter were lower than that found for the two counters 
compared. This could be expected given the changing bias between the counters with 
increasing counts. The conclusion of all these experiments was that the Matrix 96 was 
considered to be an acceptable alternative to the gamma counter for the measurement of 
^^Cr in cell-culture supernatants.
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A correlation coefficient of 0.984 between Matrix 96 and gamma counter counts was 
reported in the measurement of ^ ^Cr release from cell-mediated lympholysis assays (12). 
The present results give a correlation coefficient between the Matrix 96 and gamma 
counter of 0.985. As correlation co-efficients measure strength of linear association, 
which is not the same as agreement, and do not give a useful indication of the differences 
between two methods (14), the present approach can be considered more informative.
The Matrix 96 has quality control software which ensures that the detectors are 
operating at the optimal voltages (11). Optimal detector voltages were maintained 
throughout the period of the study. That the means of differences were below zero in 
two of three repeated Matrix 96 counts may suggest that there is some alteration of the 
samples during counting and would caution against using repeated measurements of the 
same samples for the analysis of clinical results.
Sample preparation was also found to be easier for the Matrix 96 than for a gamma 
counter. When this is considered with the ability to count 96 samples simultaneously, the 
use of the Matrix 96 gave faster, more easily obtained, yet comparable results.
After this initial assessment the Matrix 96 was used to count ^^Cr-release in CTLp assays 
of 45 samples from cardiac transplant recipients, and was found to be a rapid and 
convenient method for counting large numbers of limiting dilution assays.
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2. Assessm ent of natural killer-like activity in the CTLp assay.
2.1. K562-directed cytotoxicity in CTLp assays.
K562-directed cytotoxicity was present in CTLp cultures in an assay between HLA- 
identical siblings and in three assays between unrelated individuals with varying numbers 
of HLA mismatches. Comparable lysis of K562 targets has previously been reported in 
CTLp cultures (50 % specific lysis at 10"^  responders with 5 units/ml IL-2), together with 
increased proportions of CD56 +ve cells (335).
As expected, a low CTLp frequency (3 CTLp per million peripheral blood MNC) was 
found in the assay of HLA-identical siblings. Specific lysis of K562 was lower in this 
assay than at equivalent responder cell numbers in the assays of unrelated individuals. 
The K562“directed cytotoxicity in the assay of HLA-identical siblings is probably the 
result o f activation of NK-like activity by the IL-2 added to the cultures. The higher 
specific lysis of K562 at equivalent responder dilutions in the assays between unrelated 
individuals suggests that alloactivation also enhances the K562-directed activity in the 
CTLp cultures. This may be mediated by cytokines such as IL-2, IFN-y, interleukin-6 
and TNT-a, which increase the activity of NK cells (388) and are released during MLC 
(389). In future work, the cytokines released by HLA-identical and unrelated cells 
cultured in CTLp assay conditions could be measured to confirm this.
Cytotoxicity towards K562 is increased during primary MLC, but peaks at five to six 
days and returns to its initial level by day nine (354, 390). The time course of K562- 
directed cytotoxicity was not measured in the present study, so a comparison with, and
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comment on the kinetics in the primary MLC cannot be made. However, it is possible 
that alloactivation-enhanced K562-directed activity is maintained over the ten day culture 
period by the IL-2 added to the CTLp assay.
2.2. Cold target competition by stimulator-type PHA blasts of killing of K562 
targets.
The specificity of the NK-like activity was investigated by adding unlabelled target cells 
to the cytotoxicity assays. The increased lysis of K562 in the presence of unlabelled 
stimulator-type blast cells was liigher than expected from the experiment in which target 
cell ratios were determined, and this complicated the interpretation of these assays. This 
increased lysis of K562 could have been mediated directly by the unlabelled PHA blasts. 
Stimulation of lymphocytes with PHA and IL-2 induces cytotoxicity towards tumour cell 
targets (391, 392) and such cytotoxicity could be responsible for the augmented killing 
of K562. The IL-2 added to the PHA blast cultures, as well as IL-2 and other cytokines 
released by the PHA-activated T cells would also be expected to enhance the activity of 
NK cells present in the PHA cultures (153, 388).
An alternative explanation considered was that the PHA blast cells, although washed 
before being added as competitors, continued to release cytokines in sufficient amounts 
to enhance the NK-like activity in the CTLp assay cultures. This could explain why 
augmentation of NK-like activity shows apparent dose dependency, with lysis of K562 
not seen at higher responder cell numbers. The amount of cytokine available to each
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effector would be reduced at high cell numbers, with less enhancement of NK-like 
activity. However, cytokine gene expression by activated T cells is rapid and short­
lived. Increased expression of genes for IL-2 and IFN-y is detected between 1 and 4 
hours after in vitro stimulation of peripheral blood mononuclear cells with PHA or anti- 
CD3 monoclonal antibody (393). mRNA levels for IL-2 and IFN-y peak at 5 to 8 hours, 
with a second peak of IFN-y mRNA at 20 hours (393, 394). Other cytokines are 
expressed during T lymphocyte activation, and although the expression kinetics of 
individual cytokine genes varies, the rapid accumulation of mRNA followed by the 
cessation of transcription is a general feature (87, 395).
Levels of secreted IL-2 peak within 24 hours of stimulation, whereas IFN-y can continue 
to increase for up to 40 hours (396, 397). IL-2 is removed from the culture medium by 
the stimulated lymphocytes and its activity declines to undetectable levels after 4 to 5 
days (397, 398). The PHA blasts were washed and used as competitors after 10 days of 
culture by which time cytokine expression would have ceased, therefore it seems unlikely 
that NK-like activity could be enhanced by this mechanism.
If not a cytokine-mediated effect, the abrogation of augmented lysis of K562 at higher 
responder cell numbers could be accounted for by lysis of the unlabelled PHA blast cells 
by the more numerous alloreactive CTL likely at higher responder cell concentrations.
Treatment of the PHA blast cells to inhibit their cytotoxicity could prove difficult as both 
granule-mediated and Fas-mediated mechanisms would need to be addressed without 
affecting the cytotoxic activity of effectors generated in the CTLp cultures. Granule-
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mediated cytotoxicity can be inhibited by agents such as concanamycin A (399), and Fas- 
mediated cytotoxicity can be inhibited by a soluble Fas-immunoglobulin fusion protein 
(400). The practicalities of the use of such agents would require further investigation. 
The use of a lower competitor to target ratio could permit the reduction of the 
augmented cytotoxicity, but could also reduce the ability to detect inhibition. The size of 
split-well CTLp assays makes difficult the use of different competitor : target ratios in 
the same assay. To resolve this it may be necessai*y to use effectors generated in limiting 
dilution cultures at defined effector : target ratios, but this would not fully reflect CTLp 
assay conditions, which was the intention in these experiments.
K562 cell lysis was not inhibited in any of the assays, although the possibility that 
inhibition may have been masked by the augmented cytotoxicity seen in the presence of 
unlabelled stimulator-type blasts cannot be excluded. Specific lysis of K562 was similar 
at higher responder cell numbers with and without competitors.
2.3. Cold target competition by K562 cells of killing of stimulator-type targets.
The addition of excess unlabelled K562 cells did not significantly change the CTLp 
frequency estimates in four out of five assays, including two assays of cardiac transplant 
patients tested against their donors. In one assay (number 9), also of cells from a cardiac 
transplant recipient, there was a reduction in CTLp frequency in the presence of 
unlabelled K562 cells, but this assay exhibited non-single hit kinetics.
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Three of the ten CTLp assays were not consistent with single-hit kinetics. The increased 
number of manipulations required for the competitor assays could have introduced error, 
resulting in deviations from single-hit kinetics. The use of fewer ^^Cr-labelled target cells 
than in the standard CTLp assay was necessaiy to achieve high competitor : target ratios 
and may have decreased the sensitivity of the assay. In split-well assays, wells which are 
positive but have low cytotoxicity may sometimes only test positive in one of the split 
wells (401), and tliis could also have influenced the results. The teclmical difficulties of 
the CTLp assay were apparent in a recent multi-centre study in which non-single hit 
kinetics were reported in about 20 % of assays (402).
Five different responder-stimulator cell combinations were tested in each type of 
inhibitor assay. The results were broadly in agreement with previous studies which 
suggested that NK-like activity is distinct from alloreactive cytotoxicity in MLC and 
CTLp assays (335, 355, 357, 358). However, NK cells express inhibitoiy receptors 
which recognise different groups of HLA alleles and inhibit the lysis of recognised target 
cells (131), so it is possible that inhibition could occur in other combinations of 
responder and stimulator cells which express different inhibitory receptors and HLA 
alleles.
Despite a lack of unequivocal evidence for NK cell-mediated allocytotoxicity in the cold- 
target competition assays undertaken, the existence of a repertoire of lysis of allogeneic 
targets by NK cells has been established (360, 362, 363). Greater consideration may 
therefore have to be given to the possible influence of NK cell activity on assays of 
cytotoxic alloreactive cells in the future. This will become clearer as more is learned of
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the nature and patterns of expression of the receptors and ligands involved in the 
regulation of NK cell- and CTL-mediated cytotoxicity.
3. Kinetics of the CTLp assays.
Several of the CTLp assays of samples from cardiac transplant patients were not 
consistent with single hit kinetics. When material was available such assays were 
repeated. Acceptable clii  ^values were found in 5 of 9 repeated assays, but invalid 
kinetics were still present in 9 of 44 donor assays and 9 of 44 party assays. In most
cases, repeated assays gave CTLp frequencies with overlapping confidence intervals, 
even when the chP values indicated non-single hit kinetics.
The reasons for these invalid results are not clear. In assays with many reactive 
precursors growth was vigorous at high responder cell numbers and this could have led 
to nutrient or cytokine depletion or cell overcrowding. The responder cell dilutions were 
chosen to enable a broad range of frequencies to be estimated. However, with the 
retrospective knowledge that most frequencies remained high after transplantation, this 
problem may have been avoided by the use of a different dilution series.
Cellular interactions can produce non-single hit kinetics (329). The non-single hit 
kinetics obsei*ved here could not be clearly identified with previously described limiting 
dilution curves (329), so it is uncertain if cellular interactions were involved. Such 
interactions may be unlikely in pre-transplant samples and 3’^‘* party-reactive CTLp.
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Non-single hit kinetics consistent with T cell suppression have been described after renal 
transplantation (18, 381, 403). The number of positive wells increases with increasing 
responder cell number initially, then falls, giving a limiting dilution curve with a 
characteristic V-shaped appearance. This pattern of kinetics could not be clearly 
identified in the present study. The limited numbers of patient cells available from 
samples with invalid kinetics did not permit the use of different dilutions of responder 
cells or purified responder T cells which could have been informative in these cases.
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4. Analysis o f CTLp frequency in cardiac transplant recipients.
4.1. Comparison of pre-transplant CTLp frequencies in patients grouped by the 
number of HLA mismatches with their donor.
The high donor-reactive CTLp frequencies found in pre-transplant samples reflect the 
high degree of mismatching for donor antigens in the patients studied. Donor hearts are 
not matched for the recipient’s HLA type at this centre. The median number of HLA-A, 
-B, -DR and -DQ mismatches was 5 (range 1 to 7). The range of CTLp frequencies 
found between normal individuals varies broadly with the number of HLA mismatches 
(344, 347, 404), High frequencies are also sometimes found between umelated 
individuals who are matched for HLA phenotype, with presumed specificity for 
differences in HLA antigen subtypes or HLA loci often excluded from matching, such as 
HLA-Cw (405).
The two patients with positive B cell crossmatches (GS and TF) did not have higher pre­
transplant donor-reactive CTLp frequencies than the others. This is consistent with the 
finding that sensitisation is associated with a change in the activation state, rather than 
the frequency of CTLp (406).
In the patients studied here, although lower donor-reactive CTLp frequencies were 
found in pre-transplant samples in the group with fewer HLA mismatches, no differences 
were found in 3"’ party-reactive CTLp frequencies. The degree of mismatching with the 
3‘‘* party cells (median 7 HLA mismatches, range 1 to 8) was similar to that with donors. 
The absence of a consistent relationship between CTLp frequency and HLA mismatches
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with donors and 3"^  party cells is probably due to the scarcity of well matched 
combinations and the small numbers studied.
4.2. Relation between pre-transplant CTLp frequency and acute rejection.
No correlation was found between pre-transplant donor-reactive CTLp frequency and 
acute rejection. This agrees with previous reports in cardiac (368) and renal 
transplantation (18, 407 - 409), however Hu et al. did find a positive correlation between 
pre-transplant CTLp frequency and summed rejection score in the first eighteen months 
after cardiac transplantation (19).
Other features of T lymphocytes, such as their activation state, avidity for donor cells or 
susceptibility to inhibition by immunosuppressive drugs, may be more relevant to 
rejection than the total frequency of alloreactive T cells, especially when prior 
sensitisation has occurred (410-412).
Patients who died during the follow-up period were not tested because the main aim of 
the clinical part of the study was to follow changes in CTLp frequency over a 9 to 12 
month period. It is possible, however, that the exclusion of these patients may have 
influenced this particular analysis. Testing of pre-transplant CTLp frequencies in such 
patients may be of interest in the future.
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4.3. Post-transplant CTLp frequencies in cardiac transplant recipients.
Group analysis of paired CTLp frequencies showed that donor-reactive CTLp 
frequencies decreased significantly by 3 to 7 months after transplantation, but by 9 to 15 
months were not different from pre-transplant frequencies. Within the group, however, 
individual variation was seen. In the seven patients analysed sequentially, donor-reactive 
CTLp frequencies decreased by 3 to 7 months, but thereafter, donor-reactive CTLp 
frequencies decreased further in one patient, remained unchanged in two patients and 
increased in four patients. In three of the seven patients the decrease by 3 to 7 months 
was not donor-specific, as decreases were also seen in 3"’ party-reactive frequencies. No 
consistent patterns of change were seen in 3'^ ‘* party-reactive CTLp frequencies, and these 
were above 100 per million peripheral blood MNC by 9 to 15 months in all patients.
Donor-specific CTLp frequencies decreased in three patients (IM, SS and WM) by 9 to 
15 months compared to the pre-transplant frequency. Patient WM developed a B cell 
lymphoma and CsA was discontinued two weeks before the T3 sample was taken. These 
three patients did not receive liigher total doses of CsA and azathioprine than most other 
patients, although the number of courses of steroids was to the higher end of the range 
(table 12), Closer examination of the period before the T3 sampling times showed that 
patient SS had a biopsy with grade 2 rejection one week before sampling which was 
treated by increasing CsA, azathioprine and steroids. Patients IM and WM had no 
rejection within 200 and 100 days of their T3 samples, respectively, although WM had 
rejection immediately afterwards. The doses of immunosuppression given to these three 
patients in the weeks before the T3 samples were comparable to those given to other 
patients. It is possible that the decreased CTLp frequencies in these patients were the
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result of immunosuppressive therapy over the post-transplant period, and in the case of 
SS, following late rejection. However, given that 3"^"^ party-reactive CTLp frequencies 
were not significantly different from pre-transplant frequencies for IM and SS, and 
increased over the pre-transplant frequency for WM, donor-specific hyporesponsiveness 
of CTLp cannot be excluded. Greater than 10-fold decreases in donor-reactive CTLp 
frequencies were seen in a further two patients (GM and JC), but the T3 sample CTLp 
assays did not conform to single hit kinetics and there was also a decrease in 3“* party- 
reactive CTLp frequencies, although of a much smaller magnitude. All except one of 
these five patients (GM) had three or more EMB indicating rejection in the follow-up 
period (table 11), so with the possible exception of GM could not be held to exhibit graft 
acceptance.
Increases in donor-reactive CTLp frequency over the pre-transplant value were seen in 
two patients. Such increases may be explained by in vivo expansion of donor-specific 
lymphocytes. In one instance, the patient (GF) developed a B cell lymphoma and CsA 
therapy was stopped. The sample in which the increase in CTLp frequency was found 
was taken four weeks after cessation of CsA. CsA has a median half-life of 6.4 to 8.7 
hours (413), so should have been eliminated before this time. Two weeks later the 
patient had a grade 4 rejection episode and died. In the second instance (patient TF) the 
increased CTLp frequency was in a sample taken at the time of a grade 1A EMB with 
unchanged immunosuppression. If an in vivo expansion of donor-specific lymphocytes 
had occurred in the peripheral blood of this patient it did not appear to be reflected in an 
adverse reaction in the graft.
145
Hu et al. also found varying patterns of change in CTLp frequency after cardiac 
transplantation, with donor-reactive CTLp frequencies fluctuating more in some patients 
than in others. Patients were sampled more frequently than in the present study. The 
CTLp frequencies in the ten patients studied by Hu et al. were less than about 30 per 
million peripheral blood MNC by 9 to 10 months after transplantation, and remained low 
for 1 to 5 years (19). CTLp frequencies of such low magnitude were rare in the present 
study, but the pre-transplant frequencies were also higher. The report by Hu et al. does 
not give details of the type of heart disease the patients presented with, so it is not 
known if this could account for some of the differences. There were differences in CTLp 
assay methods, however (7 days versus 10 days incubation, 20 U/ml versus 5 U/ml IL-2). 
The immunosuppression given and the degree of matching for HLA antigens was similar 
to the present study. Hornick et al. also found low CTLp ft equencies in 4 of 10 cardiac 
transplant recipients but not in samples taken less than 4 years after transplantation 
(374). The follow-up period in the present study may have been too short to 
demonstrate decreases of this magnitude. The present findings are similar to those of 
Loonen et al. who found that donor-specific CTLp frequencies were not different before 
cardiac transplantation and between 3 months and 3 years after transplantation (369).
In renal transplantation, substantial reductions in donor-reactive CTLp and HTLp 
frequencies have also been reported in only a minority of patients (379 - 381, 414). As 
in cardiac transplantation, the proportion of patients hyporesponsive to donor antigens 
may increase with time (409). A transient decrease in donor-reactive CTLp fi equencies 
similar to that seen in the group analysis and four individual patients in the present study 
was also found by Mestre et al. in a subset of renal graft recipients (18). The decrease 
was more marked, however, in the study of Mestre et al. Of possible relevance to this
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was that the renal patients in the study of Mestre et al. were better matched with their 
donors for HLA antigens than in the cardiac patients in the present study. Such 
decreases in donor-reactive CTLp frequencies may reflect the initial high 
immunosuppression administered to transplant recipients, or could be evidence of a 
short-lived tolerisation of direct allorecognition. If the latter explanation is true further 
investigation of this process would be valuable in understanding donor-specific responses 
after organ transplantation.
The reasons why some patients develop donor-specific hyporesponsiveness after 
transplantation while others do not are not understood. It has been suggested that donor 
passenger leukocytes could be involved in this process, as hyporesponsiveness is found 
more often after the transplantation of livers, which contain large numbers of 
haematopoietic cells, than after renal or cardiac transplants (380, 415). However, 
different mechanisms of graft acceptance may operate in cardiac and renal 
transplantation, compared to liver transplantation. Clonal anergy, immune deviation or 
active suppression may operate in cardiac and renal transplantation (291), whereas high- 
dose or activation induced tolerance and mechanisms dependent on lymphoid cell 
microchimerism have been proposed for liver transplantation (290, 416).
If the reduced T3 CTLp frequencies found in three patients were a result of donor- 
specific hyporesponsiveness, the clinical relevance of this is not clear. In some studies of 
renal transplant recipients, decreases in donor-reactive CTLp and HTLp were more 
common in patients with stable graft function than in those who experienced rejection 
(18, 409, 414). However, stable graft function can occur in the absence of 
hyporesponsiveness (369, 379, 380), and graft loss can occur after hyporesponsiveness
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has developed. This was shown when low frequencies of donor-directed, primed HTLp 
were found after late failure of renal grafts (417) and hyporesponsiveness of donor- 
specific cytotoxic and helper lymphocytes was found in 5 of 10 cardiac transplant 
patients with chronic rejection (374). These findings have been interpreted as evidence 
of the involvement of indirect presentation pathways in chronic rejection. It has been 
suggested in recent reports that indirect presentation may contribute to both acute and 
chronic rejection of human cardiac allografts (377, 378, 418).
4.4. Relation between post-transplant CTLp frequencies and acute rejection.
No differences were seen in post-transplant donor-reactive CTLp frequencies grouped by 
EMB grade, except in the T3 samples in which CTLp frequencies were lower in the 
group with rejection. These patients had the most biopsies indicating rejection (6 each) 
up to their T3 sample point among the patients studied, so the decreased CTLp 
frequencies may have been the result of increased immunosuppression. T3 donor-reactive 
CTLp frequencies were negatively correlated with the number of additional courses of 
steroids since transplantation, although this was not statistically significant.
Consistent with this was the finding of a significant negative correlation for the T3 
sample donor-reactive CTLp frequencies and the number of biopsies indicating rejection 
in the period from transplantation to the T3 sample. However, no correlation was seen 
with 3'"^  party-reactive CTLp frequencies in six of these patients for whom results were 
available, which suggests that the mechanism could be donor-specific.
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In a previous study a decrease in donor-specific reactivity in mixed lymphocyte cultures 
of cardiac transplant patients with one or more acute rejection episodes was attributed to 
“the occurrence of rejection and rejection therapy” (419). CML responses were not 
reduced in these patients.
An alternative explanation could be that CTLp in these patients had migrated from the 
peripheral blood to the graft. Evidence of sequestration of lymphocytes in the allograft 
during rejection has come from canine renal transplantation (420). MLC reactivity 
decreased across the allograft during unmodified rejection, and lymphocytes recovered 
from rejecting kidneys showed accelerated responses in MLC. Consistent with this was 
the finding of reduced MLC reactivity in the peripheral blood of human renal transplant 
recipients, which preceded rejection and changes in immunosuppression (421).
That decreased CTLp frequencies were associated with rejection in only the T3 samples 
in the present study suggests, however, that entrapment within the graft is not the main 
explanation and that repeated anti-rejection therapy may have had a cumulative effect on 
peripheral blood lymphocytes.
Although Reader et al. found significant differences between CTL frequencies in the 
peripheral blood of cardiac transplant patients with different rejection grades (368) this 
was not confirmed by Vaessen et al. (370), who found no relationship between total 
donor-specific CTL and rejection. The latter group found higher percentages of CTL 
resistant to inhibition by anti-CD8 monoclonal antibody in the blood during rejection, 
however, suggesting that the avidity rather than total frequency of CTL is of relevance.
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Increased frequencies of donor-specific IL-2 producing cells have also been found during 
rejection (370, 371).
The lack of a positive association between donor-reactive CTLp frequency and rejection 
in tliis and other studies may be explained if cytotoxic lymphocytes in the periphery do 
not reflect those in the graft in terms of their frequency, activation state or avidity. 
Donor-specific CTL frequencies are higher in lymphocytes derived from EMB than from 
peripheral blood (375) and committed CTL are found more often in EMB-derived cell 
lines than in peripheral blood during rejection (376). Frequencies of high avidity CTL 
resistant to inhibition by anti-CD8 monoclonal antibody are higher in patients with 
rejection than in rejection-free patients in EMB-derived cultures, but not in MLC- 
stimulated peripheral blood MNC (256). Furthermore, preferential expression of TCR 
Vp gene families seen in EMB-derived T-cell lines was not seen in peripheral blood 
T cells, suggesting clonal expansion of activated donor-specific CTL in the graft (422). 
These findings are consistent with histological evidence for an infiltration of activated 
lymphocytes during rejection (208). Donor-reactive cells in the periphery also differ in 
activation state and frequency from those in the central lymphoid organs (423), which are 
presumably also directly relevant to the host response.
Van Emmerik et al. have proposed that committed CTL with high avidity for donor cells 
are required for rejection (235, 258). Such CTL are found in EMB cultures from 
rejecting hearts and may also be detected in peripheral blood by modified CTLp assays, 
but are not reflected in total numbers of alloreactive CTLp (370). This may explain why 
the persistence of donor-specific CTLp in peripheral blood appears not to be harmful to 
the graft, as in the present study no positive correlation between donor-specific CTLp
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frequencies and rejection was found, and Loonen et al. also found no differences in 
CTLp frequencies between patients with and without rejection (369). In the absence of 
rejection, peripheral blood CTLp may be mainly naïve or low affinity cells susceptible to 
suppression by CsA and steroids (350, 352).
It is also possible that peripheral blood CTLp are not harmful because of the absence of 
activating factors such as IL-2 from helper T cells. Wijngaard et al. found 
unresponsiveness to donor cells in 7 of 10 cardiac transplant patients 3 to 27 months 
after transplantation using a cell-mediated lympholysis assay, but umesponsiveness was 
reversed in one patient when IL-2 was added to the cultures (294). Reduced numbers of 
donor-reactive IL-2-producing cells were reported in cardiac transplant patients with 
long-term acceptance of their grafts (372). Decreased frequencies of IL-2-producing 
cells do not appear to be essential to good graft function, however (379, 381), so this is 
unlikely to be the only explanation for the lack of association of peripheral CTLp 
frequencies with rejection.
CTLp reactive with donor spleen cells may not be the only CTL which contribute to 
rejection. Cytotoxicity to more relevant targets such as heart endothelial cells (259) may 
differ from that directed towards donor cells of haematopoietic origin. CTL which 
recognise tissue-specific peptides may fail to lyse lymphoid cells, as has been 
demonstrated with kidney cell lines (424, 425), and would thus not be detected in assays 
which use splenic target cells.
The lack of association of peripheral CTLp with acute rejection could also reflect the 
multifactorial nature of graft rejection, which can include DTH-type and antibody-
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mediated mechanisms (260). Finally, in vitro assays of cellular hyporesponsiveness may 
not fully reflect the situation in vivo, due to cell separation and culture resulting in the 
loss of regulatoiy mechanisms (426).
4.5. Influence of induction immunosuppression with ATG on CTLp frequency.
No differences were seen in donor-reactive or 3"* party-reactive CTLp h equencies 
between patients who received induction immunosuppression with ATG and those who 
did not. Induction immunosuppression with anti-lymphocyte globulin has been reported 
to decrease the HLA-DR-directed cytotoxicity of graft-infiltrating cytotoxic T cells after 
cardiac transplantation (427). Such an effect is unlikely to be detected by the CTLp 
method used in the present study because PHA blasts are inefficient targets for HLA 
class Il-directed cytotoxicity (235, 335), Treatment of cardiac transplant patients with 
ATG for rejection has also been reported to reduce the frequencies of donor-reactive 
committed CTL, which were replaced with CTL with lower avidity for donor antigen 
(428). Thus, although the T cells depleted by ATG treatment are replaced when 
treatment is discontinued, the replacement cells may differ from the depleted cells in 
activation state or avidity for donor antigen. That no effect of ATG induction on CTLp 
frequencies was found in the present study indicates that donor-reactive CTLp were 
replaced after ATG treatment ended. The CTLp assay method used does not distinguish 
activation status or avidity o f CTL, however, so no comment can be made on qualitative 
differences between the different treatment groups.
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5. Future work.
Further testing of most of the samples collected in this study would be limited by the 
numbers of cells remaining. Future studies undertaken to address some of the questions 
raised by the present results could be designed differently. The hypothesis that persisting 
peripheral CTLp are not harmful because they are naïve or low affinity cells could be 
tested by modified CTLp assays which identify the activation status or affinity for donor 
antigen of CTLp. Alternatively, the use of monoclonal antibodies to activation markers 
could be useful in defining activation status (377, 429). The transient decrease in donor- 
reactive CTLp frequencies in the first few months after transplantation could be 
investigated further, perhaps by more frequent sampling during this period to determine 
the kinetics of the changes. More detailed examination of the kinetics of individual 
limiting dilution assays would be informative, particularly in those patients who exhibited 
decreased reactivity towards their donors. It would also be of interest to test the same 
group of patients at later time intervals after transplantation to determine if the 
proportion of patients with decreased reactivity to donor cells in the CTLp assay 
increases with time as has been suggested by other studies (374, 409). The occurrence 
of clironic rejection could be followed in these patients. Identifying an association 
between chronic rejection and the continued presence of donor-reactive CTLp could be 
useftil in patient management. However, confirmation of the occurrence of chronic 
rejection in patients who are hyporesponsive to donor antigens in the CTLp assay would 
suggest that assays of direct allorecognition have limited usefulness in post-transplant 
patient monitoring.
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CONCLUSIONS
The Matrix 96 was comparable to the gamma counter for the measurement of ^ ^Cr- 
release in cell culture supernatants. When used to count CTLp assays of 45 samples 
from cardiac transplant recipients the Matrix 96 was found to be a rapid and convenient 
method for processing large numbers of limiting dilution assays.
Investigation of NK-like activity in CTLp assay cultures suggested that this type of 
cytotoxicity did not contribute to the CTLp frequency estimates, in agreement with most 
other reports. Knowledge of the receptors and ligands involved in the regulation of NK- 
and CTL-mediated lysis is increasing rapidly, however, and will provide a fuller 
understanding of the interactions between the different killer lymphocytes and their 
targets.
Donor-reactive CTLp frequencies decreased by 3 to 7 months after transplantation in 
most of the cardiac transplant recipients studied, but increased to pre-transplant levels by 
9 to 15 months after transplantation. Decreased donor-specific CTLp frequencies were 
found in three patients by 9 to 15 months after transplantation. This is consistent with 
several other studies in which decreases in donor-reactive CTLp frequencies were found 
in a minority of cardiac and renal transplant recipients. The clinical relevance of 
decreased CTLp frequency after organ transplantation needs ftirther elucidation.
Pre-transplant donor-reactive CTLp frequencies were not predictive of acute rejection. 
Donor-reactive CTLp frequencies were not increased during acute rejection, but donor-
154
reactive CTLp frequencies in samples taken at 9 to 15 months after transplantation were 
negatively correlated with acute rejection. Monitoring of donor-reactive CTLp 
frequencies in peripheral blood does not, therefore, appear to be useful in the study of 
acute rejection processes after cardiac transplantation.
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